TW200810751A - Singlet oxygen scavenger, anti-skin-aging agent, anti-wrinkle agent, anti-sagging agent, agent for improving moisture content in the skin, skin-whitening agent, melanin formation inhibitor, nitrogen monooxide scavenger and antioxidant, each utilizing - Google Patents
Singlet oxygen scavenger, anti-skin-aging agent, anti-wrinkle agent, anti-sagging agent, agent for improving moisture content in the skin, skin-whitening agent, melanin formation inhibitor, nitrogen monooxide scavenger and antioxidant, each utilizing Download PDFInfo
- Publication number
- TW200810751A TW200810751A TW096113903A TW96113903A TW200810751A TW 200810751 A TW200810751 A TW 200810751A TW 096113903 A TW096113903 A TW 096113903A TW 96113903 A TW96113903 A TW 96113903A TW 200810751 A TW200810751 A TW 200810751A
- Authority
- TW
- Taiwan
- Prior art keywords
- skin
- agent
- compound
- scavenger
- group
- Prior art date
Links
- 239000003795 chemical substances by application Substances 0.000 title claims abstract description 33
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 title claims abstract description 18
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 title abstract description 71
- 230000003078 antioxidant effect Effects 0.000 title abstract description 10
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 title abstract description 9
- 239000003963 antioxidant agent Substances 0.000 title abstract description 7
- 230000015572 biosynthetic process Effects 0.000 title abstract description 7
- 239000003112 inhibitor Substances 0.000 title abstract description 4
- 229940123973 Oxygen scavenger Drugs 0.000 title abstract description 3
- 238000007665 sagging Methods 0.000 title abstract description 3
- 230000001153 anti-wrinkle effect Effects 0.000 title abstract 2
- 239000007854 depigmenting agent Substances 0.000 title abstract 2
- 239000002516 radical scavenger Substances 0.000 title abstract 2
- BYRZLWJKTOLLBX-UHFFFAOYSA-N Helipyrone Chemical compound CC1=C(CC)OC(=O)C(CC=2C(OC(CC)=C(C)C=2O)=O)=C1O BYRZLWJKTOLLBX-UHFFFAOYSA-N 0.000 claims abstract description 17
- 229940126062 Compound A Drugs 0.000 claims description 60
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims description 55
- 235000013305 food Nutrition 0.000 claims description 27
- 239000000126 substance Substances 0.000 claims description 27
- 239000000203 mixture Substances 0.000 claims description 24
- 239000002537 cosmetic Substances 0.000 claims description 9
- 230000009759 skin aging Effects 0.000 claims description 8
- 230000002087 whitening effect Effects 0.000 claims description 6
- 230000008859 change Effects 0.000 claims description 5
- 238000007254 oxidation reaction Methods 0.000 claims description 5
- 230000003647 oxidation Effects 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 3
- 235000008331 Pinus X rigitaeda Nutrition 0.000 claims 1
- 235000011613 Pinus brutia Nutrition 0.000 claims 1
- 241000018646 Pinus brutia Species 0.000 claims 1
- 230000000181 anti-adherent effect Effects 0.000 claims 1
- 210000003491 skin Anatomy 0.000 description 67
- 238000012360 testing method Methods 0.000 description 35
- 210000001519 tissue Anatomy 0.000 description 34
- 230000008030 elimination Effects 0.000 description 29
- 238000003379 elimination reaction Methods 0.000 description 29
- 238000006243 chemical reaction Methods 0.000 description 25
- 239000000243 solution Substances 0.000 description 23
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 21
- 150000001875 compounds Chemical class 0.000 description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 17
- -1 ethyl hydroxy Chemical group 0.000 description 16
- 238000000034 method Methods 0.000 description 16
- 108090000623 proteins and genes Proteins 0.000 description 16
- 241000699666 Mus <mouse, genus> Species 0.000 description 15
- 239000000523 sample Substances 0.000 description 15
- 238000002835 absorbance Methods 0.000 description 14
- 239000003153 chemical reaction reagent Substances 0.000 description 14
- 238000005406 washing Methods 0.000 description 13
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
- 235000018102 proteins Nutrition 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 12
- 230000005764 inhibitory process Effects 0.000 description 11
- 239000002904 solvent Substances 0.000 description 11
- 230000014509 gene expression Effects 0.000 description 10
- CMFNMSMUKZHDEY-UHFFFAOYSA-N peroxynitrous acid Chemical compound OON=O CMFNMSMUKZHDEY-UHFFFAOYSA-N 0.000 description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
- 239000000872 buffer Substances 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- 241000283707 Capra Species 0.000 description 8
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- 229930006000 Sucrose Natural products 0.000 description 8
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 8
- 239000005720 sucrose Substances 0.000 description 8
- 108050006400 Cyclin Proteins 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 102000009339 Proliferating Cell Nuclear Antigen Human genes 0.000 description 7
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 7
- 102000003425 Tyrosinase Human genes 0.000 description 7
- 108060008724 Tyrosinase Proteins 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 150000002576 ketones Chemical class 0.000 description 7
- 238000010186 staining Methods 0.000 description 7
- 230000037303 wrinkles Effects 0.000 description 7
- XPCTZQVDEJYUGT-UHFFFAOYSA-N 3-hydroxy-2-methyl-4-pyrone Chemical compound CC=1OC=CC(=O)C=1O XPCTZQVDEJYUGT-UHFFFAOYSA-N 0.000 description 6
- NGSWKAQJJWESNS-UHFFFAOYSA-N 4-coumaric acid Chemical compound OC(=O)C=CC1=CC=C(O)C=C1 NGSWKAQJJWESNS-UHFFFAOYSA-N 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 6
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 6
- 229940125898 compound 5 Drugs 0.000 description 6
- 238000007796 conventional method Methods 0.000 description 6
- MWKFXSUHUHTGQN-UHFFFAOYSA-N decan-1-ol Chemical compound CCCCCCCCCCO MWKFXSUHUHTGQN-UHFFFAOYSA-N 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- FDPIMTJIUBPUKL-UHFFFAOYSA-N pentan-3-one Chemical compound CCC(=O)CC FDPIMTJIUBPUKL-UHFFFAOYSA-N 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- PFTAWBLQPZVEMU-HIFRSBDPSA-N (-)-catechin Chemical compound C1([C@@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-HIFRSBDPSA-N 0.000 description 5
- 229930013799 (-)-catechin Natural products 0.000 description 5
- 235000007331 (-)-catechin Nutrition 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 5
- 235000006708 antioxidants Nutrition 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 238000009395 breeding Methods 0.000 description 5
- 230000001488 breeding effect Effects 0.000 description 5
- 150000001746 carotenes Chemical class 0.000 description 5
- 235000005473 carotenes Nutrition 0.000 description 5
- CXQWRCVTCMQVQX-UHFFFAOYSA-N cis-dihydroquercetin Natural products O1C2=CC(O)=CC(O)=C2C(=O)C(O)C1C1=CC=C(O)C(O)=C1 CXQWRCVTCMQVQX-UHFFFAOYSA-N 0.000 description 5
- 230000037406 food intake Effects 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 230000005855 radiation Effects 0.000 description 5
- 239000011782 vitamin Substances 0.000 description 5
- 229940088594 vitamin Drugs 0.000 description 5
- 235000013343 vitamin Nutrition 0.000 description 5
- 229930003231 vitamin Natural products 0.000 description 5
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- DOUMFZQKYFQNTF-WUTVXBCWSA-N (R)-rosmarinic acid Chemical compound C([C@H](C(=O)O)OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 DOUMFZQKYFQNTF-WUTVXBCWSA-N 0.000 description 4
- NCGICGYLBXGBGN-UHFFFAOYSA-N 3-morpholin-4-yl-1-oxa-3-azonia-2-azanidacyclopent-3-en-5-imine;hydrochloride Chemical compound Cl.[N-]1OC(=N)C=[N+]1N1CCOCC1 NCGICGYLBXGBGN-UHFFFAOYSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 4
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 4
- JUUBCHWRXWPFFH-UHFFFAOYSA-N Hydroxytyrosol Chemical compound OCCC1=CC=C(O)C(O)=C1 JUUBCHWRXWPFFH-UHFFFAOYSA-N 0.000 description 4
- 108060003951 Immunoglobulin Proteins 0.000 description 4
- 102000011782 Keratins Human genes 0.000 description 4
- 108010076876 Keratins Proteins 0.000 description 4
- 206010036790 Productive cough Diseases 0.000 description 4
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 210000003484 anatomy Anatomy 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 229960000271 arbutin Drugs 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- QRYRORQUOLYVBU-VBKZILBWSA-N carnosic acid Chemical compound CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 description 4
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 4
- 235000005487 catechin Nutrition 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000003384 imaging method Methods 0.000 description 4
- 102000018358 immunoglobulin Human genes 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 230000008099 melanin synthesis Effects 0.000 description 4
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 4
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 238000013319 spin trapping Methods 0.000 description 4
- 210000003802 sputum Anatomy 0.000 description 4
- 208000024794 sputum Diseases 0.000 description 4
- 239000004575 stone Substances 0.000 description 4
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 4
- 150000003722 vitamin derivatives Chemical class 0.000 description 4
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 3
- NGSWKAQJJWESNS-ZZXKWVIFSA-M 4-Hydroxycinnamate Natural products OC1=CC=C(\C=C\C([O-])=O)C=C1 NGSWKAQJJWESNS-ZZXKWVIFSA-M 0.000 description 3
- AAORMQKCOWRYHX-UHFFFAOYSA-N 5-(4-aminophenyl)cyclohexa-2,4-diene-1,1,2-triamine;hydrochloride Chemical compound Cl.C1C(N)(N)C(N)=CC=C1C1=CC=C(N)C=C1 AAORMQKCOWRYHX-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- DFYRUELUNQRZTB-UHFFFAOYSA-N Acetovanillone Natural products COC1=CC(C(C)=O)=CC=C1O DFYRUELUNQRZTB-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- HYMLWHLQFGRFIY-UHFFFAOYSA-N Maltol Natural products CC1OC=CC(=O)C1=O HYMLWHLQFGRFIY-UHFFFAOYSA-N 0.000 description 3
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 102000003992 Peroxidases Human genes 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 150000001622 bismuth compounds Chemical class 0.000 description 3
- 238000011088 calibration curve Methods 0.000 description 3
- 108091006003 carbonylated proteins Proteins 0.000 description 3
- 229950001002 cianidanol Drugs 0.000 description 3
- 238000004737 colorimetric analysis Methods 0.000 description 3
- 229940126214 compound 3 Drugs 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 238000002224 dissection Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 230000001678 irradiating effect Effects 0.000 description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 3
- 235000019341 magnesium sulphate Nutrition 0.000 description 3
- 229940043353 maltol Drugs 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 3
- 108040007629 peroxidase activity proteins Proteins 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 description 2
- MTIRIKBRVALRPJ-NTMALXAHSA-N (Z)-[3-aminopropyl(propan-2-yl)amino]-hydroxyimino-oxidoazanium Chemical compound CC(C)N(CCCN)[N+](\[O-])=N\O MTIRIKBRVALRPJ-NTMALXAHSA-N 0.000 description 2
- KWOLFJPFCHCOCG-UHFFFAOYSA-N Acetophenone Chemical compound CC(=O)C1=CC=CC=C1 KWOLFJPFCHCOCG-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 238000000018 DNA microarray Methods 0.000 description 2
- 244000000626 Daucus carota Species 0.000 description 2
- 235000002767 Daucus carota Nutrition 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- SEBFKMXJBCUCAI-UHFFFAOYSA-N NSC 227190 Natural products C1=C(O)C(OC)=CC(C2C(OC3=CC=C(C=C3O2)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-UHFFFAOYSA-N 0.000 description 2
- 206010051246 Photodermatosis Diseases 0.000 description 2
- 229920001214 Polysorbate 60 Polymers 0.000 description 2
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 2
- 239000013614 RNA sample Substances 0.000 description 2
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 2
- ZZAFFYPNLYCDEP-HNNXBMFYSA-N Rosmarinsaeure Natural products OC(=O)[C@H](Cc1cccc(O)c1O)OC(=O)C=Cc2ccc(O)c(O)c2 ZZAFFYPNLYCDEP-HNNXBMFYSA-N 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 229930003756 Vitamin B7 Natural products 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 238000004378 air conditioning Methods 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000003064 anti-oxidating effect Effects 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 238000003149 assay kit Methods 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 229910052797 bismuth Inorganic materials 0.000 description 2
- 229940074360 caffeic acid Drugs 0.000 description 2
- 235000004883 caffeic acid Nutrition 0.000 description 2
- 235000021466 carotenoid Nutrition 0.000 description 2
- 230000011712 cell development Effects 0.000 description 2
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 2
- 239000007979 citrate buffer Substances 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000005202 decontamination Methods 0.000 description 2
- 230000003588 decontaminative effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000001362 electron spin resonance spectrum Methods 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 238000005538 encapsulation Methods 0.000 description 2
- 210000001339 epidermal cell Anatomy 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 230000001815 facial effect Effects 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 238000012921 fluorescence analysis Methods 0.000 description 2
- HYBBIBNJHNGZAN-UHFFFAOYSA-N furfural Chemical compound O=CC1=CC=CO1 HYBBIBNJHNGZAN-UHFFFAOYSA-N 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000003061 melanogenesis Effects 0.000 description 2
- 229940005654 nitrite ion Drugs 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 230000037311 normal skin Effects 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 239000002304 perfume Substances 0.000 description 2
- 230000008845 photoaging Effects 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 235000005875 quercetin Nutrition 0.000 description 2
- 229960001285 quercetin Drugs 0.000 description 2
- DOUMFZQKYFQNTF-MRXNPFEDSA-N rosemarinic acid Natural products C([C@H](C(=O)O)OC(=O)C=CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 DOUMFZQKYFQNTF-MRXNPFEDSA-N 0.000 description 2
- TVHVQJFBWRLYOD-UHFFFAOYSA-N rosmarinic acid Natural products OC(=O)C(Cc1ccc(O)c(O)c1)OC(=Cc2ccc(O)c(O)c2)C=O TVHVQJFBWRLYOD-UHFFFAOYSA-N 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- SEBFKMXJBCUCAI-HKTJVKLFSA-N silibinin Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@H](OC3=CC=C(C=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-HKTJVKLFSA-N 0.000 description 2
- 235000014899 silybin Nutrition 0.000 description 2
- 235000020183 skimmed milk Nutrition 0.000 description 2
- VWDWKYIASSYTQR-UHFFFAOYSA-N sodium nitrate Chemical compound [Na+].[O-][N+]([O-])=O VWDWKYIASSYTQR-UHFFFAOYSA-N 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 238000010025 steaming Methods 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- VUYXVWGKCKTUMF-UHFFFAOYSA-N tetratriacontaethylene glycol monomethyl ether Chemical compound COCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO VUYXVWGKCKTUMF-UHFFFAOYSA-N 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 235000011912 vitamin B7 Nutrition 0.000 description 2
- 239000011735 vitamin B7 Substances 0.000 description 2
- LSHVYAFMTMFKBA-TZIWHRDSSA-N (-)-epicatechin-3-O-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=CC=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 LSHVYAFMTMFKBA-TZIWHRDSSA-N 0.000 description 1
- KVJHGPAAOUGYJX-UHFFFAOYSA-N 1,1,3,3-tetraethoxypropane Chemical compound CCOC(OCC)CC(OCC)OCC KVJHGPAAOUGYJX-UHFFFAOYSA-N 0.000 description 1
- KKZZSTCINUMTGD-UHFFFAOYSA-N 1,2,2,3-tetramethylpiperidin-4-ol Chemical compound CC1C(O)CCN(C)C1(C)C KKZZSTCINUMTGD-UHFFFAOYSA-N 0.000 description 1
- VPVXHAANQNHFSF-UHFFFAOYSA-N 1,4-dioxan-2-one Chemical compound O=C1COCCO1 VPVXHAANQNHFSF-UHFFFAOYSA-N 0.000 description 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- IPOVOSHRRIJKBR-UHFFFAOYSA-N 2-ethylpropanedioyl dichloride Chemical compound CCC(C(Cl)=O)C(Cl)=O IPOVOSHRRIJKBR-UHFFFAOYSA-N 0.000 description 1
- RVBUGGBMJDPOST-UHFFFAOYSA-N 2-thiobarbituric acid Chemical compound O=C1CC(=O)NC(=S)N1 RVBUGGBMJDPOST-UHFFFAOYSA-N 0.000 description 1
- ZPSJGADGUYYRKE-UHFFFAOYSA-N 2H-pyran-2-one Chemical compound O=C1C=CC=CO1 ZPSJGADGUYYRKE-UHFFFAOYSA-N 0.000 description 1
- DNUJVGBNIXGTHC-UHFFFAOYSA-N 3,6-dihydro-2h-oxazine Chemical compound C1NOCC=C1 DNUJVGBNIXGTHC-UHFFFAOYSA-N 0.000 description 1
- IICCLYANAQEHCI-UHFFFAOYSA-N 4,5,6,7-tetrachloro-3',6'-dihydroxy-2',4',5',7'-tetraiodospiro[2-benzofuran-3,9'-xanthene]-1-one Chemical compound O1C(=O)C(C(=C(Cl)C(Cl)=C2Cl)Cl)=C2C21C1=CC(I)=C(O)C(I)=C1OC1=C(I)C(O)=C(I)C=C21 IICCLYANAQEHCI-UHFFFAOYSA-N 0.000 description 1
- WTWSDDKGKIGSJE-UHFFFAOYSA-N 5-(4-aminophenyl)cyclohexa-2,4-diene-1,1,2-triamine;tetrahydrochloride Chemical compound Cl.Cl.Cl.Cl.C1C(N)(N)C(N)=CC=C1C1=CC=C(N)C=C1 WTWSDDKGKIGSJE-UHFFFAOYSA-N 0.000 description 1
- HCAJQHYUCKICQH-VPENINKCSA-N 8-Oxo-7,8-dihydro-2'-deoxyguanosine Chemical compound C1=2NC(N)=NC(=O)C=2NC(=O)N1[C@H]1C[C@H](O)[C@@H](CO)O1 HCAJQHYUCKICQH-VPENINKCSA-N 0.000 description 1
- HUPWFLRPYYZOSH-UHFFFAOYSA-N 9-octylicosan-9-ol Chemical compound CCCCCCCCCCCC(O)(CCCCCCCC)CCCCCCCC HUPWFLRPYYZOSH-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 241001385733 Aesculus indica Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 244000251953 Agaricus brunnescens Species 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 240000000662 Anethum graveolens Species 0.000 description 1
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 1
- 235000017491 Bambusa tulda Nutrition 0.000 description 1
- 235000016068 Berberis vulgaris Nutrition 0.000 description 1
- 241000335053 Beta vulgaris Species 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 1
- 101150041968 CDC13 gene Proteins 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 1
- LSHVYAFMTMFKBA-UHFFFAOYSA-N ECG Natural products C=1C=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 LSHVYAFMTMFKBA-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000001382 Experimental Melanoma Diseases 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 229920001612 Hydroxyethyl starch Polymers 0.000 description 1
- FDQAOULAVFHKBX-UHFFFAOYSA-N Isosilybin A Natural products C1=C(O)C(OC)=CC(C2C(OC3=CC(=CC=C3O2)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 FDQAOULAVFHKBX-UHFFFAOYSA-N 0.000 description 1
- 102000005713 Keratin-1 Human genes 0.000 description 1
- 108010070514 Keratin-1 Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 239000002211 L-ascorbic acid Substances 0.000 description 1
- 235000000069 L-ascorbic acid Nutrition 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 102100031784 Loricrin Human genes 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229940124200 Melanin inhibitor Drugs 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 101150008755 PCNA gene Proteins 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 241000282320 Panthera leo Species 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- 244000082204 Phyllostachys viridis Species 0.000 description 1
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920002535 Polyethylene Glycol 1500 Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- YZCKVEUIGOORGS-IGMARMGPSA-N Protium Chemical compound [1H] YZCKVEUIGOORGS-IGMARMGPSA-N 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 239000012327 Ruthenium complex Substances 0.000 description 1
- 230000018199 S phase Effects 0.000 description 1
- 241000239226 Scorpiones Species 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- VLGROHBNWZUINI-UHFFFAOYSA-N Silybin Natural products COc1cc(ccc1O)C2OC3C=C(C=CC3OC2CO)C4Oc5cc(O)cc(O)c5C(=O)C4O VLGROHBNWZUINI-UHFFFAOYSA-N 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 239000000524 Thiobarbituric Acid Reactive Substance Substances 0.000 description 1
- FNYLWPVRPXGIIP-UHFFFAOYSA-N Triamterene Chemical compound NC1=NC2=NC(N)=NC(N)=C2N=C1C1=CC=CC=C1 FNYLWPVRPXGIIP-UHFFFAOYSA-N 0.000 description 1
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 1
- PQNPPVJWBYLFNT-UHFFFAOYSA-N [Bi].C1=CC=CC=2C3=CC=CC=C3CC12 Chemical compound [Bi].C1=CC=CC=2C3=CC=CC=C3CC12 PQNPPVJWBYLFNT-UHFFFAOYSA-N 0.000 description 1
- IKRJXOIEFBYOAX-UHFFFAOYSA-L [O-]S([O-])(=O)=O.OS(O)(=O)=O.S.[Fe+2] Chemical compound [O-]S([O-])(=O)=O.OS(O)(=O)=O.S.[Fe+2] IKRJXOIEFBYOAX-UHFFFAOYSA-L 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 239000002280 amphoteric surfactant Substances 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 239000011425 bamboo Substances 0.000 description 1
- 238000003287 bathing Methods 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000006287 biotinylation Effects 0.000 description 1
- 238000007413 biotinylation Methods 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 210000001217 buttock Anatomy 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 229940057857 capsin Drugs 0.000 description 1
- JBFKSLZFABCEAI-UHFFFAOYSA-N capsin Natural products CC(C)(O)C1CCC(C)(O1)C2CCC3(CO)C2C(O)CC4C5(C)CCC(OC6OC(CO)C(O)C(O)C6O)C(C)(C)C5CCC34C JBFKSLZFABCEAI-UHFFFAOYSA-N 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 150000001765 catechin Chemical class 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 210000000078 claw Anatomy 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 235000020057 cognac Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229910001882 dioxygen Inorganic materials 0.000 description 1
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
- 229960002768 dipyridamole Drugs 0.000 description 1
- 229940120889 dipyrone Drugs 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000012990 dithiocarbamate Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 235000021001 fermented dairy product Nutrition 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- LRBQNJMCXXYXIU-QWKBTXIPSA-N gallotannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@H]2[C@@H]([C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-QWKBTXIPSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229940029575 guanosine Drugs 0.000 description 1
- 238000007542 hardness measurement Methods 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 229940050526 hydroxyethylstarch Drugs 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 239000000677 immunologic agent Substances 0.000 description 1
- 229940124541 immunological agent Drugs 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 229910000358 iron sulfate Inorganic materials 0.000 description 1
- ZIORURYMLXPPEN-UHFFFAOYSA-J iron(2+) disulfate hydrate Chemical compound [Fe+2].O.S(=O)(=O)([O-])[O-].[Fe+2].S(=O)(=O)([O-])[O-] ZIORURYMLXPPEN-UHFFFAOYSA-J 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 239000010977 jade Substances 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 108010079309 loricrin Proteins 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 235000012680 lutein Nutrition 0.000 description 1
- 239000001656 lutein Substances 0.000 description 1
- 229960005375 lutein Drugs 0.000 description 1
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 description 1
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 229940105631 nembutal Drugs 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 1
- 239000002840 nitric oxide donor Substances 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- GSKDBLIBBOYOFU-UHFFFAOYSA-N oxadiazol-5-amine Chemical compound NC1=CN=NO1 GSKDBLIBBOYOFU-UHFFFAOYSA-N 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 150000002923 oximes Chemical class 0.000 description 1
- 229940062042 oxygen 50 % Drugs 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 208000017983 photosensitivity disease Diseases 0.000 description 1
- 231100000434 photosensitization Toxicity 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920000137 polyphosphoric acid Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 235000008476 powdered milk Nutrition 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical group CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 1
- PDPXMIXEOSVMTR-UHFFFAOYSA-N pyrene Chemical compound C1=CC=C2C=CC3=CC=CC4=CC=C1C2=C43.C1=CC=C2C=CC3=CC=CC4=CC=C1C2=C43.C1=CC=C2C=CC3=CC=CC4=CC=C1C2=C43 PDPXMIXEOSVMTR-UHFFFAOYSA-N 0.000 description 1
- ZLIBICFPKPWGIZ-UHFFFAOYSA-N pyrimethanil Chemical compound CC1=CC(C)=NC(NC=2C=CC=CC=2)=N1 ZLIBICFPKPWGIZ-UHFFFAOYSA-N 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 229930187593 rose bengal Natural products 0.000 description 1
- 229940081623 rose bengal Drugs 0.000 description 1
- STRXNPAVPKGJQR-UHFFFAOYSA-N rose bengal A Natural products O1C(=O)C(C(=CC=C2Cl)Cl)=C2C21C1=CC(I)=C(O)C(I)=C1OC1=C(I)C(O)=C(I)C=C21 STRXNPAVPKGJQR-UHFFFAOYSA-N 0.000 description 1
- 229910001925 ruthenium oxide Inorganic materials 0.000 description 1
- WOCIAKWEIIZHES-UHFFFAOYSA-N ruthenium(iv) oxide Chemical compound O=[Ru]=O WOCIAKWEIIZHES-UHFFFAOYSA-N 0.000 description 1
- 150000003317 samarium compounds Chemical class 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 229950000628 silibinin Drugs 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 229940043175 silybin Drugs 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000037394 skin elasticity Effects 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000004317 sodium nitrate Substances 0.000 description 1
- 235000010344 sodium nitrate Nutrition 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 235000013555 soy sauce Nutrition 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 150000005671 trienes Chemical class 0.000 description 1
- 108010034272 tyrase Proteins 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 description 1
- 229910052724 xenon Inorganic materials 0.000 description 1
- FHNFHKCVQCLJFQ-UHFFFAOYSA-N xenon atom Chemical compound [Xe] FHNFHKCVQCLJFQ-UHFFFAOYSA-N 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
- A61K2800/522—Antioxidants; Radical scavengers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Toxicology (AREA)
- Birds (AREA)
- Biochemistry (AREA)
- Botany (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pyrane Compounds (AREA)
- Cosmetics (AREA)
Abstract
Description
200810751 九、發明說明: 【發明所屬之技術領域】 本發明係關於雙併吡喃酮化合物A (Helipyrone A)。 【先前技術】 非專利文獻 1 (Journal 〇f ethnopharmacology 33 ( 1991 ) p51-55 )中,揭示以一般式所表示的雙併吡喃酮化合物A (Helipyrone A)具有抗菌作用。 【非專利文獻 1】Journal of ethnopharmac〇1〇gy 33 ( 1991 ) p51-55 【非專利文獻2】EsahakAli,etal·,Phyt〇chemistry, 1982,21,243-244 【發明内容】 本發明之目的是,發關於雙併合物A㈤咖歷 A)的新作用,並尋求其有效利用。 本發明之主要構成,如以下所述。 r邮η種早料,肖除劑、皮膚老化改善H岐善劑、皮膚 _改善劑、皮膚水分量改善劑、美白劑、黑色素抑制劑、一氧 =_槪帽,咖—奴⑴綱雙併吼侧 化合物 A (HeliPyrone Α)。 5 200810751 (化學式2)200810751 IX. Description of the invention: [Technical field to which the invention pertains] The present invention relates to a dipyridone compound A (Helipyrone A). [Prior Art] Non-Patent Document 1 (Journal 〇f ethnopharmacology 33 (1991) p51-55) discloses that the bispyranone compound A (Helipyrone A) represented by the general formula has an antibacterial action. [Non-Patent Document 1] Journal of ethnopharmac〇1〇gy 33 (1991) p51-55 [Non-Patent Document 2] Esahak Ali, et al., Phyt〇 chemistry, 1982, 21, 243-244 [Summary of the Invention] Yes, issue a new role for the double-blend A (five) calories A) and seek its effective use. The main constitution of the present invention is as follows. r mail η kinds of early feed, Xiao remover, skin aging improve H 岐 good agent, skin _ improver, skin moisture improver, whitening agent, melanin inhibitor, one oxygen = _ 槪 cap, coffee - slave (1) And the side compound A (HeliPyrone Α). 5 200810751 (Chemical Formula 2)
•種經口驗成物,含有丨中所記载之任 -種皮膚外用組成物,含# 員用训。 3有1中所記載之任-項用麵 種食品,含有1中所記載之任-項用劑。 種醫藥物,含有1中所記載之任-項用劑。 -種化妝品,含有i中所記載之任—項用劑。 雙併吼喃·合物A (Heli獅ne A),根據 f斤確認其具有消除單態氧、改善皮膚老化、改她文:可 膚鬆他、改善皮膚水綠、美白、抑制黑色素、消除。皮 者防正氧化卿収果,咖賴供活肢些伽^ ^或 劑、醫藥物、食品、化妝品。 新的各種用 【實施方式】 又併比口南_化合物A (Helipyrone A)是以下列一邊 表示。 、又八C1) (化學式3) 6 200810751 一般式(1) 我們可以發現,雙併補酮化合物A (HelipyrQneA)具有抑 制敵紋效果、改善皮膚老化及光老化、美白劑、抑制黑色素生成、 T化、消除單態氧、消除—氧化氮等的新作用。基於這些新的 ^ ^將其利用於化妝品組成物、食品添加材料和醫藥材料 上。 作為化妝品和食品,可以麟其改善皮膚老化及光老化、美 白劑、抑制黑色素生成、抗氧化、消除活性氧等效果,並可使用 為皮膚老錢善劑、絲化抑棚、美白劑、黑色素生成抑制劑、 抗氧化y、單怨氧消除劑、一氧化氮消除劑。 含有本發明的雙併吡喃酮化合物A (HelipyroneA)之化妝品 (包含半藥品(quasi—drug)),若用在臉部或是手、足、身體用 勺保左化妝πσ,可列舉出化妝水、乳液、乳霜、凝膠、多層型化 妝口口等。又’也能用於口紅、粉底等美容化妝品、洗面乳、洗手 礼、沐浴鮮洗淨劑、洗髮乳、贼乳、護·、生制等毛髮 用化妝品。 有本叙月之雙併吼喃自同化合物A (HeHpyr〇neA)的化妝品 半某)在雙併11比喃嗣化合物a (Helipyrone A)之外, 200810751 可用-般化妝品的組成物所使用材料。例如,可配合碳氣油 (Hydrocarbon oil)、酷類油、脂肪酸、高級醇、矽膠、固醇 (St⑽1)、神經醯胺(ceramide)等油劑,多元醇、糖、对烧 麵酸(Pym)lld〇necarboxylicAcid)、氨基酸(amin〇aci^ 甜菜驗(betaine)等保渔劑,非離子介面活性劑,陰離子介面活 性劑、陽離子介面活性劑、兩性介面活性劑、半極性介面活性劑、 ㈣脂(lecithin)料面活性劑、高分子乳化劑、水溶性高分 子、棕摘酸糊精(Palraiticaciddextrin)等增黏劑、無機粉体、 有機粉体、抗菌劑、殺菌劑、p Η調整劑、聲合劑(_咖)、 着色劑、香料、植物萃取物等等。 含有本發明的雙併吼喃g同化合物A (Helipyr〇neA)之食品, 可以直接使用雙併吼喃s同化合物A (Heli卿ne A),或加上其他 各種營養成分作為食品,也可㈣合想要的食品。例如,添加殿 叙、乳糖、麥芽糖、植物油脂粉末、可可脂末、硬脂酸(伽㈤。 acid)等適當_劑後,使时用的方法作成適合食用的形態, 例如可成形為顆粒狀、粒狀、疑劑、膠囊、糊狀等作為健康食品、 保健機能食品等。此外也可以添加至各種食品中使用,例如火腿、 香腸等食㈣品加玉食品、魚漿、竹輪等水產加工食品、麵包、 餅乾、奶油、粉乳、發酵乳製品,或添加至水、果汁、牛乳、清 冰飲料等飲料後使用也可以。 含有本發明的雙併吼喃_化合物A (fjelipyrone A)之醫藥 8 200810751 物’可與適合經口的、_投予、直腸内投予、注射 方法的固體或液體的醫_無毒性載體混合,財 二 形態進行投予。 I梁衣劑 此力員衣劑可列舉出㈣、顆粒劑、散劑、膠囊劑等固形, 溶液劑、_劑、乳劑等液劑、雜乾燥製劑等等,躺 可依製劑上的常用方法來調製。 ~ /上,的醫藥用無毒性載體’可列舉出如葡萄糖㈤ 乳糖、麵、婦、甘露糖醇(_itQl)、糊精、脂肪酸甘油醋 (glycmde)、聚乙二醇(p〇lyethylene _〇1)、經乙基殺粉 (Hydroxyethyl starch)、乙二醇、聚氧乙稀山梨醇野脂肪酸酯 polyoxyethylene Sorbitan Fatty 娜以如)、氨基酸、明 膠(gelatin)自蛋白(albumen)、水、生理食鹽水等。此外, 根據需要也可以適當添加如安定化劑、④糊、乳化劑、結合劑、 等張化劑等常用的添加劑。 〔雙併°比喃g同化合物A (Helipyrone A)的化學合成〕 關於雙併吼細化合物A (Helipyr〇neA)的化學合成,在非 專利文獻 2 (EsahakAli,etal·,• A variety of oral test substances, including any of the external skin composition described in the sputum, including #员培训. (3) The food for use in any of the items described in the first aspect, which comprises the agent according to any one of the items. The pharmaceutical preparation contains any of the agents described in 1. - A cosmetic containing any of the ingredients described in i. Bi-pyrene complex A (Heli lion ne A), according to f kg confirmed that it has the elimination of singlet oxygen, improve skin aging, change her text: skin loose, improve skin water green, whitening, inhibit melanin, eliminate . The skin is protected by positive oxidation, and the coffee is used for living limbs, medicinal materials, food, and cosmetics. A new variety of uses [Embodiment] It is also represented by the following side of the compound A (Helipyrone A). , eight C1) (Chemical Formula 3) 6 200810751 General Formula (1) We can find that the double acetophenone compound A (HelipyrQneA) has anti-stranding effect, improves skin aging and photoaging, whitening agent, inhibits melanin production, T The new role of eliminating, eliminating singlet oxygen and eliminating nitrogen oxides. Based on these new ^ ^, it is used in cosmetic compositions, food additives and medical materials. As a cosmetic and food, it can improve skin aging and photoaging, whitening agents, inhibit melanin production, anti-oxidation, eliminate active oxygen, etc., and can be used as skin aging agent, silk smear, whitening agent, melanin. An inhibitor, an antioxidant y, a single oxygen scavenger, and a nitric oxide eliminator are produced. A cosmetic (including a semi-drug) containing the bispyranone A of the present invention, and if used on the face or the hands, feet, and body, the left makeup πσ can be cited as a makeup. Water, lotion, cream, gel, multi-layer makeup mouth, etc. Also, it can be used for cosmetics such as lipsticks, foundations, facial cosmetics, facial cleansers, hand washings, bathing fresh detergents, shampoos, thieves, nursing, and raw hair. In addition to the Helipyrone A, the composition of the composition of the general-purpose cosmetics is used in addition to the compound A (HeHpyr〇neA) of the present invention. . For example, it can be blended with oils such as hydrocarbon oil, cool oil, fatty acid, higher alcohol, silicone, sterol (St(10)1), ceramide, etc., polyol, sugar, and soy sauce (Pym) )lld〇necarboxylicAcid), amino acid (amin〇aci^ beet test (betaine) and other fishery agents, nonionic surfactants, anionic surfactants, cationic surfactants, amphoteric surfactants, semi-polar surfactants, (4) Grease (lecithin) surfactant, polymer emulsifier, water-soluble polymer, palmitic acid dextrin (Palraitic aciddextrin) and other tackifiers, inorganic powders, organic powders, antibacterial agents, fungicides, p Η adjusters , a sounding agent (_coffee), a coloring agent, a fragrance, a plant extract, etc. A food containing the bis-indolyl g of the present invention and a compound A (Helipyr〇ne A), which can be directly used as a compound A (Heliqing ne A), or add a variety of other nutrients as food, or (4) the desired food. For example, add the temple, lactose, maltose, vegetable oil powder, cocoa butter, stearic acid (gamma (five) Acid) After the appropriate amount of the agent, the method for the time is made into a form suitable for eating, for example, it can be formed into a granule, a granule, a suspect, a capsule, a paste, etc. as a health food, a health-care food, etc. In addition, it can also be added to various foods. Used in foods such as ham, sausage, etc. (4) foods such as jade food, fish paste, bamboo wheels, etc., processed bread, biscuits, cream, powdered milk, fermented dairy products, or added to water, juice, milk, iced drinks, etc. It is also possible to use it later. The medicine 8 200810751 containing the bi-pyrene-based compound A (fjelipyrone A) of the present invention can be combined with a solid or liquid suitable for oral, intradermal, intrarectal or injection methods. _ non-toxic carrier mixture, the second form of the investment. I beam coating agent can be listed as (4), granules, powder, capsules and other solid forms, solutions, _ agents, emulsions, etc., dry Preparations, etc., can be prepared according to the usual methods on the preparation. ~ /, the non-toxic carrier for medicine can be exemplified by glucose (f) lactose, noodles, women, mannitol (_itQl), dextrin, fat Glycerin (glycmde), polyethylene glycol (p〇lyethylene _〇1), ethyl hydroxy powder (Hydroxyethyl starch), ethylene glycol, polyoxyethylene sorbitan fatty acid ester polyoxyethylene Sorbitan Fatty Naru , amino acid, gelatin (albumen), water, physiological saline, and the like. Further, a usual additive such as a stabilizer, a 4 paste, an emulsifier, a binder, an isotonic agent, or the like may be appropriately added as needed. [Chemical synthesis of the compound A (Helipyrone A)] [Chemical synthesis of the bismuth fluorene compound A (Helipyr〇ne A), in Non-Patent Document 2 (Esahak Ali, etal·,
Phytochemistry,1982, 21,243-244)中已有揭示。 舉例來說,本發明是如以下所述而合成。 使用400mL的己烧(hexane)為溶媒,在四氯化欽的存在下 9 200810751 以化合物 1 ··二乙酮(diethyl ketone) (3-戊酮;3-pentanone) 172g,與化合物 2:四氫-1, 4-噁唤(tetrahydro-l,4-〇xazine (嗎 琳;morpholine)) lOOOg在4°C下使其反應三個小時,以蒸顧處 理精製後得到化合物3 : (N-異丙烯基)-四氫-1,4-噁嗪 ((N-isopropenyl) - terahydr〇-l,4-〇xazine) 503.57g,回收 率 81.1%。 使用200mL的甲苯(toluene)為溶媒,將化合物3 : (N-異丙 烯基)-四氫-1,4-°惡唤((N-isopropenyl) -terahydro-l,4-oxazine) 167g與化合物4:乙基丙二酸單酰氣 (ethyl malonyl chloride) 81g在冰溫(一 17°C--11°C)甲醇 (methanol)下使其反應,合成一般式2表示的化合物5。 化學式(4)It has been disclosed in Phytochemistry, 1982, 21, 243-244). For example, the invention is synthesized as described below. Using 400 mL of hexane as a solvent in the presence of tetrachlorinated 9 200810751 with compound 1 · diethyl ketone (3-pentanone; 3-pentanone) 172 g, and compound 2: four Hydrogen-1, 4-oxo (tetrahydro-l, 4-〇xazine (morphine); lOOOg was reacted at 4 ° C for three hours, and purified by steaming to obtain compound 3: (N- Isopropenyl)-(N-isopropenyl- terahydr〇-l,4-〇xazine) 503.57 g, recovery 81.1%. Compound 3: (N-isopropenyl)-terahydro-l, 4-oxazine 167g and compound using 200mL of toluene as solvent 4: ethyl malonyl chloride 81 g was reacted at ice temperature (17 ° C - 11 ° C) under methanol to synthesize the compound 5 represented by the general formula 2. Chemical formula (4)
OH 人 一般式(2 ) 以添加2N鹽酸終結化合物3與化合物4的反應,經氯仿 (chloroform)萃取後’進行硫酸鎮(Magnesium)乾燥處理。接 下來,在反應溶液中依次加入曱苯2〇〇mL及25%塩酸4〇〇虬,以 液一液分配回收曱苯層。將曱苯層以〇1N鹽酸4〇〇mL洗淨,以硫 酸鎂乾燥處理後,以真空脫水器(evap〇rat〇r)除去曱苯,得到 200810751 橙色油狀溶液。將一公斤的多磷酸(Polyphosph〇ric acid)加入 此洛液,在110 c〜118°C環化後合成化合物5。將化合物5冷卻 至室溫,進行氯仿萃取回收,以硫酸鎂乾燥處理後,以真空脫水 器除去氯仿。將固狀物以矽膠色譜分析法(silica gel chromatography)(氯仿:曱醇=50 : 1 ( v/v ))得到橘色固 形化合物5共45· 7g。本反應的回收率為18. 3%。 此化合物5在1N鹽酸的存在下以甲醛(formaldehyde)進行 聚合反應’化學合成化合物6雙併吡喃酮化合物a (Helipyrone A)。將化合物5 45· 7g溶於乙醇(ethanol) 460mL中,在濃復酸 2· 5mL的存在下將曱醛(37%) 247· 81g在79°C下進行回流反應, 使析出結晶。將此結晶以乙醇3〇〇mL洗淨,得到白色結晶的雙併 吨喃酮化合物A (Helipyrone A) 34· Olg。本反應的收率為η β %。 所得的雙併吼喃酮化合物A (Helipyrone Α),物性質如以下 所示。 外觀:白色結晶 NMR 頻譜(400 MHz,溶媒;CDC13) 卞-賺 占=a 1· 231、b 1· 969、c 2. 554、d 3. 616、e 11· 199 13C NMR (400 MHz、溶媒;CDCh) 占=1—169.335 (t) H-168.499 (m),G->160.160 (m) 11 200810751 F-108.709 (m)5 Ε->1〇1· 592 (t) , D->24. 368 (qt), C->19.176 (t),B—11.689 (qt),A—9·476 (q) (化學式5)OH person General formula (2) The reaction of the compound 3 with the compound 4 is carried out by adding 2N hydrochloric acid, and after extraction with chloroform, it is subjected to a magnesium sulphate drying treatment. Next, 2 〇〇 mL of hydrazine and 25% of citric acid were sequentially added to the reaction solution, and the benzene layer was recovered by liquid-liquid partitioning. The phthalic acid layer was washed with 4 〇〇 mL of 〇1N hydrochloric acid, dried with magnesium sulfate, and then deuterated with a vacuum dehydrator (evap〇rat〇r) to obtain an orange oily solution of 200810751. One kilogram of polyphosphoric acid was added to the solution, and compound 5 was synthesized after cyclization at 110 c to 118 °C. The compound 5 was cooled to room temperature, subjected to chloroform extraction, and dried over magnesium sulfate, and then evaporated to remove chloroform. The solid was subjected to silica gel chromatography (chloroform: decyl alcohol = 50:1 (v/v)) to obtain an orange solid compound 5 of 45·7 g. 3%。 The recovery of the reaction was 18.3%. This compound 5 was polymerized by formaldehyde in the presence of 1 N hydrochloric acid. Chemical synthesis of compound 6 bispyranone compound a (Helipyrone A). The compound 5 45·7 g was dissolved in 460 mL of ethanol, and furfural (37%) 247·81 g was refluxed at 79 ° C in the presence of concentrated hydrochloric acid in a concentration of 2.5 mL to precipitate crystals. The crystals were washed with 3 mL of ethanol to give white crystals of the product of Helipyrone A (34). The yield of this reaction is η β %. The obtained bisacedanone compound A (Helipyrone®) has the properties as shown below. Appearance: white crystal NMR spectrum (400 MHz, solvent; CDC13) 卞- earning = a 1 · 231, b 1 · 969, c 2. 554, d 3. 616, e 11· 199 13C NMR (400 MHz, solvent) ;CDCh) 占=1—169.335 (t) H-168.499 (m), G->160.160 (m) 11 200810751 F-108.709 (m)5 Ε->1〇1· 592 (t) , D- >24. 368 (qt), C->19.176 (t), B-11.689 (qt), A-9.476 (q) (Formula 5)
(化學式6)(Chemical Formula 6)
分子量:320.341g/mol (質量分析) 分子式:Cl7H20〇6 (質量分析)Molecular weight: 320.341g/mol (mass analysis) Molecular formula: Cl7H20〇6 (mass analysis)
熔點:218 — 220°C 〔抗氧化能評價〕 以雙併^比喃i同化合物A (HelipyroneA)進行單態氧(siglet state molecular oxygen )消除作用之評價。評價法為將2, 2, 6, 6_Melting point: 218 - 220 ° C [Evaluation of antioxidant energy] The evaluation of the elimination of siglet state molecular oxygen by the compound A (Helipyrone A) was carried out. The evaluation method will be 2, 2, 6, 6_
四曱基-4-哌啶二醇(2, 2, 6, 6-tetramethy;L-4-piperidinol ) (4-0HTEMP)作為自旋捕捉劑(SpinTrappingReagents)以 自旋捕捉法進行測定。首先’以市面上的平底%孔微盤 (miCr〇Plate)將任意濃度調製而成的雙併化合物ATetramethyl-4-piperidinol (2, 2, 6, 6-tetramethy; L-4-piperidinol) (4-0HTEMP) was determined as a spin trapping agent (SpinTrapping Reagents) by spin trapping. First, the bis-compound A prepared by any concentration on a commercially available flat bottom % microplate (miCr〇Plate)
12 200810751 (Dimettiylformamide)水溶液 0· lmL,接著是蒸餾水 〇· 〇2mL,與 100mM之4-OH TEMP水溶液0· 04mL、0· ImM的玫瑰紅瓊脂(rose bengal)水溶液〇· 〇4mL混合,成為〇· 2mL的混合液。將此作為光 增感反應(photosensitization reaction)的光源,由微盤之背 面以極大波長530nm的發光二極體(緑色LED)照射20分鐘使其 產生單態氧。把此混合液移到ESR用扁平水溶液槽,以e SR光 譜(spectrum)進行測定。由ESR光譜之強度求出單態氧的消除 率,將消除率相對濃度標繪圖表、求出50%抑制濃度I C50的値。 再者,同時求出既存的多酚(polyphenol)化合物(水飛萄賓 (silybin)、3, 4-二羥基苯基乙醇(dihydroxyphenyl ethanol )、 (―)一兒茶素(catechin)、(一)一表兒茶素沒食子酸酯 (Epicatechin gal late)、槲皮素(quercetin)、迷迭香酸 (rosmarinic acid)、鼠尾草酸(carnosic acid)、咖啡酸(caffeic acid)、麴酸(K〇jicacid)、/9 一胡蔔素)的IC5〇的値以作為比 較。結果請參見表1。 為了從此結果而明朗化,和其他的多盼化合物作比較,可斷 定雙併吼姻化合物A (Helip卿eA)在較低濃度下可消除單態 氧。也就是說,可以明白表示出雙併0比喃酮化合物A (祕默㈣ A)具有優秀的單態氧消除作用。 13 200810751 表1 試料 單態氧50%抑制濃度(#M) 雙併11比喃酮化合物A 51.52 水飛薊賓 195. 51 3, 4-二羥基苯基乙醇 184.86 (一)一兒茶素 184.89 (一)一表兒茶素沒食子酸酯 111.40 槲皮素 119.67 迷迭香酸 107.06 鼠尾草酸 131.95 咖啡酸 278. 15 麴酸 83.15 /5 —胡蔔素 436. 40 〔黑色素生成抑制試驗〕 以市面販賣之6孔實驗JUL (well plate),分別都使用老鼠 B16黑色素瘤(melan〇ma)細胞,在5%C〇2、37°C之条件下,以含 培養液10%FBS (牛胎兒血清)的DMEM培養至覆蓋整個實驗皿。 添加lOOnMaMSH作為黑色素生成刺激劑,同時添加〇 〇〇〇1%的 雙併吡喃酮化合物A,持續培養72小時。溶媒條件為含有1〇%fbs 之DMEM培養基,但考慮到雙併他喃酮化合物a的溶解度,在全部 14 200810751 的實驗孤加入0· 2%乙腈(acetonitrile)。培養終了之後,回收 細胞質部分(cytosolic fraction),以0· 1N氫氧化鈉作驗處理 使黑色素色素溶解,測定405nm的吸光度(ABS)。 黑色素生成抑制率以下列公式算出: 黑色素生成抑制率[%] = 1〇〇χ{1— (ABS[Sample]) / (ABS[Control]) }12 200810751 (Dimettiylformamide) aqueous solution 0 · lmL, followed by distilled water 〇 〇 2mL, mixed with 100 mM 4-OH TEMP aqueous solution 0. 04mL, 0 · 1mM rose red agar (rose bengal) aqueous solution 〇 · 〇 4mL, become 〇 · 2mL of the mixture. This was used as a light source for a photosensitization reaction, and a single-state oxygen was generated by irradiating a light-emitting diode (green LED) having a maximum wavelength of 530 nm for 20 minutes from the back surface of the microdisk. This mixture was transferred to a flat aqueous solution tank for ESR, and measured by an e SR spectrum. The elimination rate of singlet oxygen was determined from the intensity of the ESR spectrum, and the elimination rate was plotted against the concentration standard table to determine the enthalpy of 50% inhibition concentration I C50 . Furthermore, the existing polyphenol compound (silybin, 3, 4-dihydroxyphenylethanol, (-) catechin, (a) is simultaneously determined. ) Epicatechin gal late, quercetin, rosmarinic acid, carnosic acid, caffeic acid, tannic acid (K〇jicacid), /9-husin) IC5〇 is used as a comparison. See Table 1 for the results. In order to be clear from this result, compared with other polyantibiotic compounds, it can be concluded that the bismuth compound A (Helipqing eA) can eliminate singlet oxygen at a lower concentration. That is, it can be clearly understood that the bis-oxanone ketone compound A (Secret (4) A) has excellent singlet oxygen elimination. 13 200810751 Table 1 Sample singlet oxygen 50% inhibitory concentration (#M) Bis 11 ketone compound A 51.52 Silibinin 195. 51 3, 4-dihydroxyphenylethanol 184.86 (a) catechin 184.89 (a) a catechin catechin 111.40 quercetin 119.67 rosmarinic acid 107.06 carnosic acid 131.95 caffeic acid 278. 15 citric acid 83.15 /5 - capsin 436. 40 [melanogenesis inhibition test] Using the commercially available 6-well test JUL (well plate), mouse B16 melanoma (melan〇ma) cells were used, respectively, at 5% C 〇 2, 37 ° C, with culture medium 10% FBS (cattle). DMEM of fetal serum) was cultured to cover the entire test dish. lOOnMaMSH was added as a melanin-producing stimulating agent, and 1% dipyridone compound A was added thereto, and culture was continued for 72 hours. The solvent conditions were DMEM medium containing 1% fbs, but considering the solubility of the bis-tagpanone compound a, 0.2% acetonitrile was added in the experiment of all 14 200810751. After the end of the culture, the cytosolic fraction was recovered, and the melanin pigment was dissolved by treatment with 0. 1N sodium hydroxide, and the absorbance at 405 nm (ABS) was measured. The melanin production inhibition rate is calculated by the following formula: Melanogenesis inhibition rate [%] = 1〇〇χ{1—(ABS[Sample]) / (ABS[Control]) }
Control :含有〇· 2%乙腈的MEM培養基Control : MEM medium containing 〇·2% acetonitrile
Sample :含有〇· 2%乙腈、添加〇· 0001%雙併吡喃_化合物A (DMEM培養基) 此一結果,添加〇· 0001%雙併吡喃酮化合物Λ時,抑制221 %±&4(S.D·)黑色素生成。 · 〔抑制因紫外線照射形成皺紋之 實驗〕 對無毛鼠長期持續照射微弱的紫外線,而形成皺紋、鬆弛等 $膚老化縣以作為動物模型,對祕難實施試驗,此時給予 • 并匕南綱化合物A的飼料傲食,並解析其影響。 L實驗動物 種•系統•性別 種·老氣、系統:H〇s:HR1 (無毛鼠)、性別:雌 •飼育開始週齡 15 200810751Sample : Containing 〇·2% acetonitrile, adding 〇· 0001% bispyridinium-Compound A (DMEM medium) As a result, when 〇· 0001% bispyranone compound Λ was added, 221 %±&4 was inhibited. (SD·) melanin production. · [Inhibition of wrinkles caused by ultraviolet radiation] The hairless rats are continuously exposed to weak ultraviolet rays for a long period of time, and wrinkles, slacks, and the like are formed as an animal model, and tests are carried out on secrets. The compound A's feed is arrogant and its effects are resolved. L experimental animals species • system • gender species • old gas, system: H〇s: HR1 (no hair), gender: female • breeding start age 15 200810751
II
I 從5週大開始飼育,同時開始混合飼料银食。 II·飼育環境 設定溫溼度:24±1°C、相對溼度55±5% 空調設備:全新風(all fresh)方式 照明時間:12時小時自動點燈、熄燈方式 飼育設備:塑膠製籠子5隻/一籠 飼料:自由攝取粉末滅菌飼料做―l(oriental酵母工業(股 或疋MF-1中分別混合雙併π比喃酮化合物A(Helipyrone A)各〇. 〇1 % (w/w)、〇· 05% (w/w)、〇· 1% (w/w),或混合具優秀抗氧化効 果的召胡蘿蔔素 0.01% (w/w)、0.05% (w/w)。 111 ·试驗日程表 紫外線照射條件··十個星期内隔日(間隔一天)使用紫外線 燈,在不使用拘束帶下照射UV-A波14J/cm2(照射時間約1分鐘)、 UV B波20mJ/cm (照射時間約50分鐘)。1〇週(35次)的全照射 量為 UV-A 波 490J/cm2、UV-B 波 700mJ/cm2。 關於持續紫外線照射的組別,在解剖24小時前實施最後一次 ’、外線知、射。解剖18小時前進行絶食。解剖前以雜侵入性方法, 使用簡易水分計(Moisture Checker™、scaia製)來測定皮膚水 分量。 16 200810751I started breeding at 5 weeks of age and started mixing feed silver food. II· breeding environment setting temperature and humidity: 24±1°C, relative humidity 55±5% Air conditioning equipment: all fresh (all fresh) lighting time: 12 hours hour automatic lighting, light out mode breeding equipment: plastic cage 5 / One cage feed: Free ingestion of powdered sterile feed for "l (oriental yeast industry (mixed or 疋MF-1 mixed with double π ketone ketone compound A (Helipyrone A) 〇. 〇 1 % (w/w) 〇· 05% (w/w), 〇·1% (w/w), or a mixture of carotenoids with excellent antioxidant effects of 0.01% (w/w), 0.05% (w/w). The test schedule ultraviolet irradiation conditions··Using an ultraviolet lamp on the next day (every day) in ten weeks, the UV-A wave is irradiated 14J/cm2 without irradiation (the irradiation time is about 1 minute), and the UV B wave is 20 mJ/cm. (Ignition time is about 50 minutes). The total exposure amount of 1 week (35 times) is UV-A wave 490J/cm2, UV-B wave 700mJ/cm2. For the group of continuous ultraviolet irradiation, it is implemented 24 hours before dissection. The last time, 'external line knowledge, shot. Anatomy 18 hours before hunger strike. Before the dissection, using a simple moisture meter (Moisture Checker) TM, scaia) to measure the amount of skin water. 16 200810751
I ( 以戊巴比妥(nembutal)進行鱗,拍下外觀。並採取皮膚 背部的複本(replica)。 經由解剖,取出肝臓、令血阳从 叮職王血回收、回收背部及腹部皮膚。 馬上將臟器冷束保存,全血則進行離心分離(3,刪g,驗, 室溫),將pl讓(血裝)回收予以冷康保存。至於皮膚,則將背 部的一定面積以鮑音(Bouin)淡闳仝、,处 rU /夜口疋,以備組織染色用,其他則 冷凍保存。 把焦點放在外觀上皮膚狀態的頸部的下垂⑶职㈣及背部 的敏紋(Wrmkle),以Bi_ DL等等的定義(Ph〇t〇chemI (with nembutal), take the appearance and take a replica of the back of the skin. After dissection, remove the liver sputum, recover the blood from the blood of the lord, and recover the back and abdomen skin. The organ is stored in a cold bundle, and the whole blood is centrifuged (3, delete g, test, room temperature), and the pl is allowed to be recovered (blood pack) for cold preservation. As for the skin, the back area is abalone. (Bouin) is the same as the other, in the rU / night mouth, for tissue dyeing, others are frozen. Focus on the appearance of the skin in the neck of the sagging (3) position (four) and back of the sensitive pattern (Wrmkle) , as defined by Bi_ DL, etc. (Ph〇t〇chem
Photobiol. (1987) Vol.46, No.3,pp367-pp78)>W^〇 也就是說’⑽下觸定義紐航。躺有_的檢體則給予 中間值的Q. 5。皺紋分數的資料圖表化後如圖1所示。 • 0分 無法辨認出鈹紋的發生。 在#止狀恶下’無法辨認出相對於脊椎方向的垂直線條,或 是只能猶微觸的程度,而隨著侧的運祕會消失。 • 1分 此夠明確辨認輕微的敏紋。 月b夠辨相對於脊椎方向的垂直線條,而隨著個體的運動 其線條會消失。 • 2分 17 200810751 能明確辨認中程度的皺紋。 月匕夠辨"忍出相對於脊椎方向的線條,即使隨著個體的運動, 線條也不會消失而永久存在。 •3分 能明確辨認很深的皺紋。 處夠辨認出相對於脊椎方向的線條,並能辨認出線條的影 子即使隨著個體的運動,線條也不會、;肖失而永久存在。 人在敵紋分數上,相對於接受紫外線照射1〇週的(控制組) 如組為2· 4,接受紫外線照射1G週、配合混人Q·聰併吼喃 ^ 口物A的MF-1食用組為〇· 1,接受紫外線照射1〇週、配合混 =〇· 05%雙併吼喃酮化合物A的MF—丨食用組為◦· 2,接受紫外線 :射10週、配合混人Q· Q1%雙併吼喃酮化合物A的.1食用組 為^ ’其齡:的生成均受卿著的抑制。1Q勒不照射紫外線 舍食用MF-1 (控制組)的組別,其敵紋分數為〇·2,經由配合食 Ζ 〇· 05〜0.1雙併吼細化合物A,m照射紫外麵產生的皺紋則 完全被抑制。 “從皮膚所觀制的絲,可轉知雙併化合物A具有 、著的抑制敞紋效果。儘食老鼠的雙併吼喃酮化合物A,—天的攝 取堇為处,以體表面積換算式y= (3ντχ) 2換算成對人的投予量 的話’相等於520mg/日/60kg體重。若則.〇1%混合飼料自由 攝取’則相當於約52呢/曰/60kg if重,是可以當成食品不會過 18 200810751 量攝取的可能量。 此外’攝食具有抗氧化作用的胡蘿8素的組別,並未顯 示出皺紋抑制效果。 接文紫外線照射10週、配合G· Q5% $ —胡蘿蔔素的ΜΙΜ食 用組,敵紋分數為2· 〇,接受紫外線照射1〇週、配合〇· 〇1%石― 胡蘿蔔素的MF-1食用組,敵紋分數為2 3。 〔伴隨紫外線照射之皮膚乾燥之抑制〕 解剖别以非侵入性方法,用簡易水分計來測定皮膚水分量 (Moisture Checker™、scala製),每隻測定5回,比較各組的平 均的測定値。皮膚水分量的測定結果如圖2所示。 紫外線照射10週+ MF-1 (控制組)食用組,皮膚水分量降低 下壬乾燥状態(皮膚水分量31· 4%)。相對的,紫外線照射10週 間+配合雙併吡喃酮化合物A的MF-1食用組,配合0· 1%雙併吡 喃酮化合物A的皮膚水分量為41· 3%,配合〇· 05%的皮膚水分量 則為40.2%,配合0.01%的皮膚水分量為38.2%,保持40%左 右、顯著的高皮膚水分量。雙併°比喃酮化合物A配合食用組的皮 膚水分量,比起不照射紫外線而經過10週的MF-1 (控制組)食用 組皮膚水分量35· 5%,數值更高。 〔伴隨紫外線照射的皮膚硬化的抑制〕 19 200810751 使用彈簧式硬度計(JIS C型)皮膚黏彈性測定裝置 (Vesmeter : E-lOOS/WaveCyber製),由背部連接尾巴部分向頭 部2cm起,腰椎右側〇· 5cm的部位測定三次求出平均硬度。皮膚 硬度的測定結果如圖3所示。 一般而言,硬度作為皮膚黏彈性的指標,其數値越高則表示 皮膚老化在進行,皮膚彈性降低。 紫外線照射10週+ MF-1 (控制組)食用組,皮膚硬化的程度 很顯著(度數15· 4)。相對的,紫外線照射1〇週間+配合雙併吡 喃酮化合物A的MF-1食用組,配合〇. 1%雙併吡喃酮化合物a的 硬度度數為8· 1,配合0· 05%的硬度度數則為9· 1,配合〇· 〇!% 的硬度度數為9. 1,比起不照射紫外線而經過10週的MF—丨(控制 組)食用組的硬度度數7· 2,只有稍微硬化的程度,硬化被抑制。 〔伴卩返|、外線A?、射皮膚組織中的幾基化(Carb〇nylafi〇n)蛋白質 生成的抑制〕 氧化蛋白質其中之一的羰基化蛋白質,係使用〇xybl〇tTM (CHEMIC0N社)來評價。具體的方法如下。秤出溼重量約 的老鼠皮膚,在4°C下加入含有蛋白酶抑制劑(prcrtease inhibitor cocktail)的分解緩衝液(Lisys buffer) (ρΗ=7· 4) 〇· 2πα,使其均質(homogenize)化,以12, 〇〇〇gx2〇分鐘離心後, 將上清液過濾,以Bradford的方法測定蛋自度。各個蛋白質 20 200810751 试料取20//g,將其羰基·pH化。以電泳分析法(SDS_pAGE)分 離蛋白質,使用蛋白質轉印裝置轉印至PVDF膜上。經轉印後的膜 在常溫下,於保存在4°c下含5%脫脂牛奶的PBS ( —)溶液中進 行區隔(blocking) 30分,將脫脂牛奶(Skimmiik)以PBS( — ) 洗淨後,在4°C下與抗DNPH抗體進行反應一個晚上,洗淨後,與 維生素H (biotin)化的抗老鼠IgG進行反應i小時。洗淨後,使 用螢光檢測裝置(ECL PLUS)讓,膜感光,在醫療用自動顯像 t置上把圖像轉寫。結果如圖4所示。 紫外線照射10週+MF-1 (控制組)食驗,縣化蛋白質量 的相對值是259.4。相對的,紫外線照射1()週間+配合雙併吼喃 酮化合物A的MF-1食驗,合〇. 1%雙併化合物a的幾 基化蛋白質量的姉值為25. 3,配合化蛋白質量_ 對值則為35. 6 ’配合〇. 〇1%基化蛋白f量的相對值 1化蛋白質的生成受到1/1G〜1/5的抑制。比起不照射紫外線 而經過1G週的MF-1 (控制組)食用組之相對值23. 7,與配合〇 1 %雙併吼俩化合物A的食胁的化蛋㈣量的相對值y ,’梅佩編物_抑制伴隨 i外線妝射而產生的羰基化蛋白質的生成。 #1=抗氧化作„蔔素之_,从能得知對 叛基化蛋白質的生成有抑制效果。 t 照射紫外線Η)週並配合G观P —胡蘿_素的㈣食用 21 200810751 ’照射紫外線1 〇週並配合 .基化蛋白質量的相對値為 組,羰基化蛋白質量的相對値為153. i, 〇 · ο 1 %冷一胡蘿蔔素的MF-1食用組,羯 190· 7。 〔伴隨紫外線照射皮膚組織中的8_經基(hydrQxy) _2’令票吟 核(guanosine) (8-OH dG)生成之抑制〕 8-OHdG以免疫組織化學的方法加以測定。動物解剖時,切下 皮膚組織背部之尾巴連接處向頭部2cm’腰椎右側Q. 5咖部位的皮 膚w,以鮑音液固定,及石壤包埋來保存皮膚組織。適當地製 作3/zm厚的切片’基於習知方法來脱石壤和親水化。在〇.謹棒 檬酸(citric acid)緩衝液(PH6.0)中微波處理五分鐘來進行 抗原賦活化。冷卻至室溫後,在常溫下以含有〇· 3%過氧化氫的曱 醇進行反學化應20分鐘,以阻礙其内因性的過氧化酶 (peroxidase)。水洗、10mM PBS (-)洗淨後,以山羊血清75 倍10mM PBS ( —)的稀釋溶液實施五分鐘的微波處理使其區隔, 之後將血清去掉,以1次抗体(Μ5· 1:日研SEIL(股)製)5^41 微波處理20分鐘使抗體反應。以lOmM PBS ( —)進行兩次洗淨, 添加稀釋三百倍維生素Η化(biotinylation)的二次抗體(維生 素Η化山羊免疫球蛋白(globulin) Μ ; DAK0製),進行五分鐘的 微波處理使抗體反應。以lOmMPBS (—)進行兩次洗淨,添加ABC 試薬(ABC-HRP; Vectastain製)進行五分鐘的微波處理使其反應。 22 200810751 * 使用DAB (3, 3-二氨基聯苯胺鹽酸鹽:j)AK〇製)為成色試劑,在 常溫下放置三分三十秒使其反應。水洗後,基於習知方法來脫水, 進行包埋處理。在顯微鏡下觀察皮膚組織的染色狀況。使用M〇be Photoshop取得圖像,將圖像中一定面積裡的染色處以nih Imaging數值化。結果如圖5所示。 紫外線照射1〇週+ MF-1 (控制組)食用組,8—〇H邠的相斐 值是5. 89。相對的,紫外線照射1〇週間+配合雙併^比喃嗣化合來 A的MF-1食用組’配合〇. 1%雙併吼侧化合物a的8—〇h邠量 的相對值為G. 87,配合G. 05%雙併*細化合物A的請量d( 的相對值顺〇. 9卜配合G·㈣雙物細化合物A的㈣^ 置的相對值為丨.1G,8, dG量的生成受到i5/⑽〜19/剛齡 :dG _值i•⑻,照射紫外線但配合⑽ 生的8:::恤可,著地抑制伴隨紫外線照射而產 此外,食用具有抗氧化作用的 示_,沉的生成有抑制效果。…”素之組別,並未顯 8.:::广_配合〇.〇5% Η蘿《素的.i食 ㈣邱里的相對値為5 2 艮用、、且 胡蘿《素的㈣食_,8 = $外線1G週並配合G. Gl%yS - “用組8,邠量的相對値為 23 200810751 〔伴隨紫外線照射皮膚組織中的過氧化脂質生成之抑制〕 用螢光分析測量皮膚組織的TBARS(硫代巴比妥酸反應性物質 (thiobarbituric acid reactive substances),nmol/g 濕重撕的 weight)。枰量各組織的濕重量約2〇〇mg,以1· 15% KCllml均裝 後’依序添加1/遣硫酸4ml、10%鎢礙酸(Tungstophosphoric Acid) 〇· 5ml,進行3, OOOrpm、lOmin的離心分離。消除上清的雜 質’添加TBA試劑(硫代巴比妥酸/醋酸緩衝液),於沸騰水浴槽 中加熱反應1小時。於TBARS的定量用,另外用加入m3—四 乙氧基丙烷(1,1,3, 3-Tetraethoxypropane)的試料進行TBA反 應,製作檢量線。結果如圖6所示。 加熱反應結束後,用冰冷(ice—cold)降回室溫,加入5mi 正丁醇(n- butyl alcohol)攪拌後,以 3, OOOrpm、lOmin 的條 件離心分離,回收上層的正丁醇層提供螢光分析(Ex 515nm,Em 553nm)。螢光強度計是使用HITACHI f—2〇〇〇。 結果,紫外線照射10週+ MF-1 (控制組)食用組組織中的過 氧化脂質量是50.8nmol/mg,相對的,紫外線照射1〇週間+配合 雙併σ比喃酮化合物A的MF-1食用組,配合〇· 1%雙併α比喃顚]化合 物Α的組織中的過氧化脂質量是3〇· 9nm〇1/mg,配合〇· 〇5%雙併 吼喃S同化合物A的組織中的的過氧化脂質量是33· 7nmol/mg,配 合0· 01 %雙併吼喃酮化合物A的組織中的的過氧化脂質量是 24 200810751 44. 8圓i/mg,過氧化脂質的生成受到6/ι〇〜9/ι〇的抑制。紫外 線照射10週間+配合〇. 雙併吼麵化合物a的食用組及配合 0. 5%的食用組的過氧化脂f量,與不照射紫外線而經過週的 MF-i (控做)食肋之_中的過氧化脂質量^咖I〆呢, 是相同的程度。因此,雙併吼_化合物A可以顯著地抑制伴隨 紫外線照射而產生的過氧化脂質的生成。 此外’伽具有抗氧化作㈣6 —胡蘿蔔素之_,幾乎沒 有顯示出對過氧化脂質的生成有抑制效果。 照射紫外線10週並配合〇· G5% A —姆s素的MF—i食用 組’過氧化脂質量為46· 9nmol/mg,照射紫外線1〇週並配合〇· 〇1 胡蘿蔔素的MF-1食用組,過氧化脂質量為51. lnm〇1/呢。 〔使用ESR法的一氧化氮消除能的評價〕 對 100//M 的 SNAP(S-亞硝基(nitroso)—n—乙醯基(acetyi) -D,L-青黴胺(penicillamine),同仁化學製),比較雙併吡喃酮 化合物A與作為氧化防止劑、已知的(―)兒茶素(sigma製)兩 者的一氧化氮消除能。 關於自旋捕捉劑,使用混合N-甲基—D-還原葡糖胺 (glucamine)-二硫代氨基曱酸鹽(dithiocarbamate)(以下稱 為MGD。從LAB0TEC (股)購買)與硫酸鐵(π )水溶液而調製的 (MGD) 2-Fe2+複合體。此複合體藉由與一氧化氮反應形成(MGD) 25 200810751Photobiol. (1987) Vol.46, No.3, pp367-pp78)>W^〇 In other words, '(10) touches the definition of New Zealand. The sample with the _ lying is given the intermediate value of Q. 5. The data of the wrinkle score is graphically shown in Figure 1. • 0 points Unable to recognize the occurrence of crepe. Under #止状恶, the vertical line relative to the direction of the spine cannot be recognized, or the degree of the touch can only be touched, and the secret of the side disappears. • 1 point This is enough to clearly identify the slight sensitivity. The month b is enough to distinguish the vertical line from the direction of the spine, and the line disappears as the individual moves. • 2 points 17 200810751 Clearly recognizes moderate levels of wrinkles. The moon is enough to distinguish the lines relative to the direction of the spine, even if the individual moves, the lines will not disappear and exist forever. • 3 points Clearly recognize deep wrinkles. It is enough to recognize the line relative to the direction of the spine, and can recognize the shadow of the line. Even with the movement of the individual, the line will not be; In the score of the enemy pattern, compared with the exposure group that received ultraviolet radiation for 1 week (control group), such as group is 2.4, receiving ultraviolet radiation for 1G week, and mixing with MF-1 of Q·cong and 吼 ^^ The edible group was 〇·1, and the MF-丨 edible group that received UV irradiation for 1 week and mixed with 〇·05% bis-anionone compound A was ◦·2, and received ultraviolet light: 10 weeks, mixed with Q. · The edible group of Q1% bis-anionone compound A was inhibited by the age of ''old''. 1Q Le does not irradiate the ultraviolet ray to eat MF-1 (control group) group, the enemy pattern score is 〇 · 2, through the combination of Ζ 〇 · 05~0.1 double and fine compound A, m irradiated wrinkles on the ultraviolet surface It is completely suppressed. "The silk from the skin can be transferred to know that the compound A has the effect of inhibiting the openness. The double-indolone compound A of the rat is eaten, and the ingestion of the day is used as the surface area conversion formula. y= (3ντχ) 2 is equivalent to 520mg/day/60kg body weight when converted to the amount of human administration. If 〇1% mixed feed is freely ingested, it is equivalent to about 52%/曰/60kg if heavy, yes It can be used as a food. It will not be able to take the amount of 18 200810751. In addition, the group of carrots with anti-oxidation effect does not show the effect of wrinkle suppression. The ultraviolet radiation for 10 weeks, with G· Q5% $ 胡萝卜 胡萝卜 ΜΙΜ , , , , , , , , — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — Inhibition of skin drying by ultraviolet irradiation] The skin moisture content (Moisture CheckerTM, manufactured by Scala) was measured by a simple moisture meter by a non-invasive method, and each measurement was performed five times, and the average measurement of each group was compared. The measurement results of the moisture content are shown in Fig. 2. After external exposure for 10 weeks + MF-1 (control group), the skin moisture content decreased in the sputum dry state (skin moisture content 31.4%). In contrast, UV irradiation for 10 weeks + with dipyridone compound A In the MF-1 edible group, the skin moisture content of the 0.1% dipyridone compound A was 41.3%, and the skin moisture content of the 〇·05% was 40.2%, and the skin moisture content of 0.01% was 38.2%, maintaining a high skin moisture content of about 40%. The amount of skin moisture in the edible group combined with the ketone compound A was compared with that of the MF-1 (control group) after 10 weeks without irradiating ultraviolet rays. The skin moisture content is 35·5%, and the value is higher. [Suppression of skin hardening accompanied by ultraviolet irradiation] 19 200810751 A spring type hardness tester (JIS C type) skin viscoelasticity measuring device (Vesmeter: E-100S/WaveCyber) is used. From the back part of the tail to the head 2cm, the right side of the lumbar vertebrae 5cm is measured three times to determine the average hardness. The skin hardness measurement results are shown in Figure 3. In general, hardness as an indicator of skin viscoelasticity, the number The higher the 値, the skin aging During the treatment, the skin elasticity decreased. Ultraviolet irradiation for 10 weeks + MF-1 (control group) in the edible group, the degree of skin hardening was significant (degrees 15.4). In contrast, ultraviolet irradiation for 1 week + with dipyridone The MF-1 edible group of Compound A is combined with 〇. 1% bispyranone compound a has a hardness of 8.1, and the hardness of 0. 05% is 9.1, and 〇· 〇!% The hardness degree was 9.1, and the hardness degree of the MF-丨 (control group) edible group which passed 10 weeks without irradiating ultraviolet rays was 7.2, and the degree of hardening was only slightly hardened, and the hardening was suppressed. [With 卩 | 、, 外 外 A?, inhibition of protein formation in the skin tissue (Carb〇nylafi〇n)] The carbonylated protein of one of the oxidized proteins is 〇xybl〇tTM (CHEMIC0N) To evaluate. The specific method is as follows. Weigh the mouse skin with a wet weight, and add a prcrtease inhibitor cocktail (Lisys buffer) (ρΗ=7·4) 〇·2πα at 4 °C to homogenize it. After centrifugation at 12, 〇〇〇gx2 for 5 minutes, the supernatant was filtered, and the egg self-determination was measured by the method of Bradford. Each protein 20 200810751 The sample was taken at 20/g, and its carbonyl group was pH-formed. The protein was separated by electrophoresis analysis (SDS_pAGE) and transferred to a PVDF membrane using a protein transfer device. The transferred film was blocked at room temperature for 30 minutes in a PBS (-) solution containing 5% skim milk at 4 ° C, and skimmed milk (Skimmiik) was washed with PBS (-). After the reaction, the reaction was carried out with an anti-DNPH antibody at 4 ° C overnight, and after washing, it was reacted with vitamin H (biotin) anti-mouse IgG for 1 hour. After washing, the fluorescent detection device (ECL PLUS) is used to make the film sensitive, and the image is transferred to the medical automatic image t. The result is shown in Figure 4. Ultraviolet irradiation for 10 weeks + MF-1 (control group) food test, the relative value of the county protein amount was 259.4. The 姊 , , 紫外线 紫外线 紫外线 紫外线 紫外线 紫外线 紫外线 紫外线 紫外线 紫外线 紫外线 紫外线 紫外线 紫外线 , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , The protein quality _ the value is 35.6. The complex value of the amount of 〇1% of the proteinized protein f is 1/1G~1/5. The relative value y of the amount of the egg (four) of the MF-1 (control group) consumed by the MF-1 (control group) after 1G week without irradiation with ultraviolet rays, and the relative value of the egg (four) of the flank of the compound A of the bismuth compound 'Maype's _ suppresses the formation of carbonylated proteins produced by the appearance of i-line makeup. #1=Antioxidant is used as the _ 素素, which can be known to have an inhibitory effect on the production of tick-based proteins. t Irradiation of ultraviolet rays Η) and with G Guan P - Carotenoids (4) Edible 21 200810751 'Irrigation The relative enthalpy of the amount of carbonylated protein was 153. i, 〇· ο 1 % cold-carotene MF-1 edible group, 羯190·7. [Inhibition of guanosine (8-OH dG) production by 8-hydraulic (hydrQxy) _2' in the skin tissue irradiated with ultraviolet light] 8-OHdG was measured by immunohistochemistry. Cut the tail joint of the back of the skin tissue to the head 2cm' of the right side of the lumbar vertebrae. The skin w of the 5th part of the lumbar vertebrae is fixed with the abalone liquid and embedded in the stone to preserve the skin tissue. Make a 3/zm thick slice appropriately. 'Desaturated soil and hydrophilization based on a conventional method. Microwave treatment for five minutes in citric acid buffer (pH 6.0) for antigen activation. After cooling to room temperature, at room temperature Decontamination with decyl alcohol containing 3% 3% hydrogen peroxide should be carried out for 20 minutes to block The endogenous peroxidase was washed with water, 10 mM PBS (-), and then subjected to microwave treatment for 5 minutes in a diluted solution of goat serum 75 times 10 mM PBS (-), and then the serum was removed. The antibody was reacted by microwave treatment for 1 minute with 5 times of the antibody (Μ5·1, manufactured by SEIL Co., Ltd.), washed twice with 10 mM PBS (-), and diluted with 300 times of vitamin oxime ( Biotinylation of secondary antibody (vitamin deuterated goat immunoglobulin (globulin) Μ; manufactured by DAK0), subjected to microwave treatment for five minutes to react the antibody. Wash twice with 10 mM PBS (-), add ABC test (ABC- HRP; Vectastain) is subjected to microwave treatment for five minutes to react. 22 200810751 * Use DAB (3, 3-diaminobenzidine hydrochloride: j) AK) as a color forming reagent, place three-thirds at room temperature After 10 seconds, the reaction was carried out. After washing with water, it was dehydrated and embedded in a conventional method. The staining of the skin tissue was observed under a microscope. Images were taken using M〇be Photoshop, and the staining in a certain area of the image was Nih Imaging numerical The results are shown in Fig. 5. Ultraviolet irradiation 1 week + MF-1 (control group) edible group, 8-〇H邠's phase value is 5.89. In contrast, ultraviolet irradiation 1 week + double ^ 比 的 嗣 的 的 的 的 的 的 的 MF MF MF 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 The relative value of A is the same as the value of A. The relative value of (4) is the same as the value of (.1G, 8, and the amount of dG is generated by i5/(10)~19/old age. : dG _value i•(8), which can be irradiated with ultraviolet rays, but can be combined with (8) raw 8::: shirts, and it is possible to suppress the production of ultraviolet rays by the exposure of the ground. In addition, the food has an antioxidant effect, and the formation of sediment has an inhibitory effect. ..."The group of the prime, did not show 8.::: wide _ with 〇. 〇 5% dill "sugar.i food (four) Qiu Li's relative 値 is 5 2 艮,, and the carrots (4) Food _, 8 = $1G circumference and with G. Gl%yS - "With group 8, the relative enthalpy of sputum is 23 200810751 [Suppression of lipid peroxide formation in skin tissue with UV irradiation] Fluorescence analysis TBARS (thiobarbituric acid reactive substances, nmol/g wet weight torn weight) of skin tissue was measured.枰 枰 各 各 各 各 各 各 各 各 各 各 各 各 各 各 各 各 各 各 各 各 各 各 各 各 各 各 各 各 各 各 各 各 各 各 各 各 各 各 各 各 各 各 各 各 各 各 各 各 各 各 各 各 各 各 各 各 各 各 各 各Centrifugation of lOmin. Elimination of impurities in the supernatant 'The TBA reagent (thiobarbituric acid/acetic acid buffer) was added and the reaction was heated in a boiling water bath for 1 hour. For the quantification of TBARS, a TBA reaction was carried out by using a sample containing m3-tetraethoxypropane (1,1,3,3-Tetraethoxypropane) to prepare a calibration curve. The result is shown in Figure 6. After the end of the heating reaction, it was cooled to room temperature with ice-cold, stirred with 5 mi of n-butyl alcohol, and then centrifuged at 3, OOO rpm for 10 min to recover the upper n-butanol layer. Fluorescence analysis (Ex 515 nm, Em 553 nm). The fluorescent intensity meter uses HITACHI f-2. As a result, the mass of peroxidized lipid in the tissue of the edible group was 50.8 nmol/mg in the ultraviolet irradiation for 10 weeks + MF-1 (control group), and the ultraviolet ray was irradiated for 1 week and the MF of the bis- σ-pyrone compound A was matched. 1 edible group, with 〇 · 1% bis-α 比 顚 顚 顚 Α Α Α Α Α Α Α Α Α Α 组织 组织 组织 组织 组织 组织 组织 组织 组织 组织 组织 组织 组织 组织 组织 组织 组织 组织 组织 组织 组织 同 同 同 同 同 同 同 同The mass of the peroxylipid in the tissue is 33·7 nmol/mg, and the mass of the peroxylipid in the tissue of the 0.01% bis-indolone compound A is 24 200810751 44. 8 round i/mg, peroxidation Lipid production is inhibited by 6/ι〇~9/ι〇. Ultraviolet irradiation for 10 weeks + with 〇. The consumption group of double 吼 吼 compound a and the amount of peroxide peroxide f in the 5% edible group, and MF-i (control) ribs after weeks without irradiation of ultraviolet rays The quality of the peroxidized fat in the _ is the same degree. Therefore, the dimercapto-compound A can remarkably suppress the formation of peroxidized lipids accompanying ultraviolet irradiation. In addition, gamma has an antioxidant effect as (4) 6-carotene, which has almost no inhibitory effect on the production of lipid peroxide. The MF-i edible group irradiated with ultraviolet rays for 10 weeks and with 〇·G5% A- s s s-peroxide has a mass of 46·9 nmol/mg, and irradiated with ultraviolet rays for 1 week and cooperated with MF-1 of 〇·〇1 carotene. Lnm〇1/呢。 The edible group, the quality of the lipid peroxide is 51. lnm〇1/? [Evaluation of Nitric Oxide Elimination Energy by ESR Method] For 100//M SNAP (S-Nitroso-nitro-acetyi-D, L- Penicillamine, Tongren Chemically, the nitric oxide elimination energy of the dipyridone compound A and the known (-) catechin (manufactured by Sigma) as an oxidation preventing agent were compared. Regarding the spin trapping agent, a mixed N-methyl-D-reduced glucamine-dithiocarbamate (hereinafter referred to as MGD. purchased from LAB0TEC (share)) and iron sulfate (using (MGD) 2-Fe2+ complex prepared by π) aqueous solution. This complex is formed by reaction with nitric oxide (MGD) 25 200810751
I 葡 2-Fe2+-NO的複合體,產生ESR光譜強度,所以藉由測量在一氧化 氮消除劑在分別濃度的ESR光譜,來測量一氧化氮的消除能。 50mM 一水合硫酸鐵(Π )( Iron (瓜)sulfate n-hydrate) 溶媒·蒸館水100//L(最後濃度5mM)、50mMMGD溶媒PBS(ρH7·4) 100 //L(隶後〉辰度5mM)、受檢物質溶媒:10%乙腈(acet〇nitri le) 100//L、100mM 磷酸緩衝液 699//L、100mM SNAP 溶媒 〇· 1M 氫氧 化納1 //L (敢後濃度i〇〇#μ)依序加進1. 5ml容量的微量離心管 (Eppendorf Tubes),從添加SNAP開始,以25°C攪拌反應10分 鐘。 由於10分種的25°C反應,從SNAP放出一氧化氮,構成(MGD) 2-Fe2+-NO的信號強度比=i : 1 : 1的3個波峰。此信號強度是根據 受檢物質增減多少,以此評價一氧化氮消除能。具體而言,以不 添加受檢物質的控制組的信號強度(C)為基準,從添加受驗物質 時的信號強度(S)根據下列公式求得一氧化氮消除率,如圖7所 示0 一氧化氮消除率=(1 一S/C) xlOO (%) 結果,雙併ϋ比喃i同化合物A在25//Μ〜200//Μ的範圍,濃度 依存地一氧化氮消除率提高(於25//Μ為32. 4%、於50 //Μ為52· 6 %、於 100//Μ 為 63· 6%、於 2〇〇4 為 80.1%),IC50 濃度為 51· 4 //Μ ’相對於此’兒茶素於、100//Μ中一氧化氮消除率 不過分別是5.6%、11· ,於mo#μ為31.4%、於500為 26 200810751The complex of I-gluco-2-Fe2+-NO produces an ESR spectral intensity, so the elimination energy of nitric oxide is measured by measuring the ESR spectrum of the respective concentrations of the nitrogen oxide eliminator. 50mM iron sulphate monohydrate (iron) (iron (sulfur) sulfate n-hydrate) solvent · steaming water 100 / / L (last concentration of 5mM), 50mMMGD solvent PBS (ρH7 · 4) 100 / L (after the 〉 chen Degree 5 mM), test substance solvent: 10% acetonitrile (acet〇nitri le) 100 / / L, 100 mM phosphate buffer 699 / / L, 100 mM SNAP solvent 〇 · 1M sodium hydroxide 1 / L (dare concentration i 〇〇#μ) A microcentrifuge tube (Eppendorf Tubes) of 1.5 ml capacity was sequentially added, and the reaction was stirred at 25 ° C for 10 minutes from the addition of SNAP. Nitrogen oxide was evolved from SNAP due to a 10 minute 25 ° C reaction, and the signal intensity ratio of (MGD) 2-Fe2+-NO was composed of three peaks of =i:1:1. This signal intensity is based on how much the test substance is increased or decreased to evaluate the nitric oxide elimination energy. Specifically, based on the signal intensity (C) of the control group to which the test substance is not added, the signal intensity (S) at the time of adding the test substance is determined according to the following formula, as shown in FIG. 0 Nitric oxide elimination rate = (1 - S / C) xlOO (%) As a result, the ratio of di-pyrene-pyrene to the same compound A in the range of 25//Μ~200//Μ, the concentration-dependent nitric oxide elimination rate Increase (in 25//Μ is 32.4%, 50/Μ is 52.6 %, 100//Μ is 63.6%, and 2〇〇4 is 80.1%), IC50 concentration is 51· 4 //Μ 'relative to this' catechins, 100//Μ, the elimination rate of nitric oxide is only 5.6%, 11·, respectively, mo#μ is 31.4%, and 500 is 26 200810751
II
I 47· 4%的一氧化氮消除率。IC50濃度計算為547//M。 本次使用的機器及機器條件設定如以下所示。 機器:JEOL JES TE200、X-band ESR 裝置(ΙΟΟΚΗζ、日本電 子公司製) 機器條件設定: 中心場 center field : 335. 0±5. OmT、 微波力 microwave power : 4mW、 調制振幅 modulation amplitude : 0· lmT、 增益 gain : 500、 時間常數 time constant : 0· 1 秒、 掃描時間scanning time : 1分鐘 〔使用比色法(Griess法)的一氧化氮消除能〕 浴液中存在的一氧化氮在水溶液中極為不穩定,因此除了 ESR 法以外’藉由測量作為一氧化氛氧化物的亞硝酸離子,間接評價 一氧化氮量。同時也對已知的抗氧化物質的(―)兒茶素、麥芽醇 (maltol)、P-香豆酸(c〇umaric acid)進行評價,而與雙併吼 喃合物A相比較。根據Griess法的測量,是使用漏&試 劑組(AssayKit) -Cn (Colorimetric)(同仁化學製)。 使用 N0C-5 (1-羥基(hydr〇xy) _2_氧(〇χ〇) _3—氨丙基 (-__yl))-3-異丙基(iSQPn)pylM_ 三氮稀(Wne)) 27 200810751 j同仁化子公司製)作為—氧化氮產生劑,直到使用前以〇·射 氧化納的驗浴液於一2〇。〇冷;東保存。根據試劑組中的緩衝液里 (pH-7· 6 ’以下稱為「緩衝液」)稀釋⑽⑽倍調整為_域的 /辰度’藉此產生-氧化氮。作為一氧化氮供體⑷财)而開發出 的N0C-5,於驗溶液中雖然穩定,但在中性及酸性條件下,是:生 成-氧化亂的不穩定化合物(25度,在ρΗ7· 4條件下半衰 分鐘)。 於市售的平底96孔培養皿添加受驗物質溶媒··包含1%乙腈 的緩衝液(ρΗ=7· 6) 40//L使受驗物質的濃度變化。之後,添加月 20 // L緩衝液(ρη=7· 6 ),添加1 〇〇 # Μ的N〇c—5溶液4〇 “ L以烈 C反應2小日寸。反應結束後,添加5〇以試劑組中的μ咖試气 A後放置5分鐘,繼續各添加50 “l的Griess試劑β後放置1〇" 分鐘進行呈色反應(CQlor reaetiQn)。在多功能微盤分析儀测量 540nm的吸光度。在各受驗物質的添加濃度的吸光度以s⑽,不= 文驗物質的控制組的吸光度以C54〇,不含受驗物質及N〇c—5的空白 組以By。,用下列公式算出一氧化氮消除率,如表2、圖8 所示。 -氧化氮消除率(%) =lGGx(l— (S54。—B54〇//(Cs4。—β54。)) 檢量線是由代替NOC-5溶液的亞硝酸鈉溶液在〇〜1〇〇#Μ的 濃度區域設定的檢體的吸光度所作成,求得溶液中的亞硝酸離子 濃度。可由此亞硝酸離子濃度求得由N0C-5溶液所產生的一氡化 28 200810751 氮濃度。 一氧化氮消除能的強度是,以在本實驗系統中消除50%的濃 度(IC50、// Μ)來比較。 由100//Μ的N0C-5溶液,生成47. 0//Μ的一氧化氮作為亞硝 酸離子。此時,根據添加受驗物質的吸光度的降低,即,可知為 一氧化氮的消除活性。 表2 添加濃度 UM) 一氧化氮消除率(%) 雙併吼喃酮 化合物A (-)兒茶素 麥芽醇 p-香豆酸 400 79.4 69.7 75.8 73.4 300 73.7 64.5 70.9 64.7 200 69.4 47.1 66.3 46.2 100 64.9 27.5 51.2 33.5 50 45.4 18.3 36.3 26.9 雙併吡喃酮化合物Α在50//Μ〜400//Μ的範圍,可知其濃度 依存地一氧化氮的消除能,IC50濃度為36.7//Μ ◦另一方面,(-) 兒茶素、麥芽醇、Ρ-香豆酸的IC50濃度為190. 0//Μ、94. 0//Μ、 187. 4//Μ。可確認雙併吡喃酮化合物Α具有優異的一氧化氮消除 能0 29 200810751 ^ >果可知道本發明的雙併π比喃綱化合物A明顯能消 除-乳化II,對於作為血管系、神經系統、免疫系的藥劑相當有 用。此雙紗_化合物A具有消除存在生體内過細 恢復正常的—氧域敍的侧,及_—氧聽補產生的情 況時而預先投予、防止生體内產生過剩的—氧化氮的作用。即, 本說明書中雙㈣侧化合物A的—氧錢齡能,並非是指將 存姐體内全部的—氧化氮完全消除,而是指消除生體内過剩的 -氧化氮,進行t鱗喊為生體維持上適當的份量。 〔使用比色法的過氧亞硝酸消除能〕 雙併吼喃_匕合物A的過氧亞硝酸鹽(per〇xynitrite)消除 能力,是根據Griess法’使用N〇2/N〇3試劑組(AssayKit) (Colorimetric)(同仁化學製)測量。 同時也對已知的抗氧化物質(_)兒茶素、麥芽醇、p_香豆酸 進行評價,而與雙併吡喃酮化合物A相比較。 於市售的平底96孔培養皿添加受驗物質溶媒:包含丨%乙腈 的緩衝液(ρΗ=7· 6) 40//L使受驗物質的濃度變化。之後,於分別 的孔中添加試劑組中的還原酶(reductase) 10//L,及輔酶 (coenzyme) 10//L。 添加40//L的SIN-1 (3- (4-嗎琳基Morpholinyl)悉尼亞胺 sydnonimine鹽酸鹽hydrochloride) 50//M作為過氧亞硝酸產生 30 200810751 9 劑’使其於37 C反應2小時。反應結束後,添加50//L試劑組中 的Griess試劑A後放置5分鐘,繼續各添加50 //L的Griess試 劑B後放置1 〇分鐘進行呈色反應。在多功能微盤分析儀測量54〇舰 的及光度。X驗物質的吸光度以义4。,不含受驗物質的控制組的吸 光度以C540,不含受驗物質及SIN-1的空白組的吸光度以b540,用 下列公式异出過氧亞硝酸消除率(%),如表3、圖9所示。 過氧亞硝酸消除率(%) =100x (1—(S540 — B540) / (C540 — B540)) 檢量線是由代替SIN-1溶液的硝酸鈉溶液在0〜100//M的濃 度區域設定的檢體的吸光度所作成,求得溶液中的硝酸離子濃 度。可由此硝酸離子濃度求得由SIN-i溶液所產生的過氧亞硝酸 濃度。 過氧亞硝资消除能的強度是,以在本實驗系統中消除5〇%的 濃度(IC50、//M)來比較。 結果,在控制組中,從50#M的SIN-1產生過氧亞硝酸8.18 //M ’關於消除其過氧亞硝酸5〇%的咖濃度,相對於雙併吨喃 酮化合物A為24. 04/zM,麥芽醇為31. 84mM、p-香豆酸為31仙 #M、()兒余素為705. 6yM’顯示出雙併吡喃酮化合物a具有優 異的過氧亞硝酸消除能。 31 200810751 t 表3I 47· 4% nitric oxide elimination rate. The IC50 concentration was calculated to be 547//M. The machine and machine condition settings used this time are as follows. Machine: JEOL JES TE200, X-band ESR device (ΙΟΟΚΗζ, manufactured by JEOL Ltd.) Machine condition setting: Center field: 335. 0±5. OmT, microwave power: 4mW, modulation amplitude modulation amplitude: 0· lmT, gain gain: 500, time constant time constant: 0·1 second, scanning time: scanning time: 1 minute [Nitric oxide elimination energy using colorimetry (Griess method)] Nitric oxide present in the bath solution in aqueous solution It is extremely unstable, so in addition to the ESR method, the amount of nitric oxide is indirectly evaluated by measuring the nitrite ion as an oxidizing oxide. At the same time, (-) catechin, maltol, and c〇umaric acid, which are known as antioxidant substances, were evaluated, and compared with the di-indole A. According to the measurement of the Griess method, the Assay Kit - Cn (Colorimetric) (manufactured by Toray Chemical Co., Ltd.) was used. Use N0C-5 (1-hydroxy(hydr〇xy)_2_oxy(〇χ〇)_3-aminopropyl(-__yl))-3-isopropyl (iSQPn)pylM_triazide (Wne)) 27 200810751 j, manufactured by Tongren Chemical Co., Ltd.), as a nitrogen oxide generator, until the use of a bath solution of ruthenium oxide is used at a temperature of 2 Torr. Cold; East save. The nitrogen oxide is produced by diluting (10) (10) times the buffer in the reagent group (referred to as "buffer" below pH-7·6') to the _ domain. N0C-5, which was developed as a nitric oxide donor (4), is stable in the test solution, but under neutral and acidic conditions, it is an unstable compound that generates and oxidizes (25 degrees, at ρΗ7· 4 conditions under half-life). The test substance solvent was added to a commercially available flat-bottom 96-well culture dish. The buffer containing 1% acetonitrile (ρΗ=7·6) 40//L was used to change the concentration of the test substance. After that, add 20/8 L buffer (ρη=7·6), add 1 〇〇# ΜN〇c-5 solution 4〇“L reacts with 2 times of strong C. After the reaction, add 5 〇 Place the test chamber A in the reagent group for 5 minutes, continue to add 50 μl of Griess reagent β, and place 1 〇" minute for color reaction (CQlor reaetiQn). The absorbance at 540 nm was measured on a multi-function microdisk analyzer. The absorbance at the added concentration of each test substance was s (10), not = the absorbance of the control group of the test substance was C54 〇, and the blank of the test substance and N〇c-5 was not used. The nitric oxide elimination rate was calculated by the following formula, as shown in Table 2 and Figure 8. - Nitrogen oxide elimination rate (%) = lGGx (l - (S54. - B54 〇 / / (Cs4 - - β54.)) The calibration curve is replaced by NOC-5 solution of sodium nitrite solution in 〇~1〇〇 The absorbance of the sample set in the concentration region of #Μ is determined to determine the concentration of nitrite ions in the solution. The concentration of nitrite ions can be used to determine the nitrogen concentration of the oxidized 28 200810751 produced by the NOC-5 solution. The intensity of the nitrogen elimination energy was compared with the concentration of 50% (IC50, / / Μ) in the experimental system. From 100 / / Μ N0C-5 solution, the formation of 40.7 / / Μ nitric oxide As the nitrite ion, at this time, according to the decrease in the absorbance of the test substance added, that is, the elimination activity of nitric oxide is shown. Table 2 Addition concentration UM) Nitric oxide elimination rate (%) Bis-indanone compound A (-) catechin maltol p-coumaric acid 400 79.4 69.7 75.8 73.4 300 73.7 64.5 70.9 64.7 200 69.4 47.1 66.3 46.2 100 64.9 27.5 51.2 33.5 50 45.4 18.3 36.3 26.9 Bipyranone compound Α at 50// Μ~400//Μ range, it can be seen that its concentration depends on the elimination of nitric oxide, IC50 thick 3//Μ ◦ ◦ ◦ ◦ ◦ ◦ ◦ ◦ ◦ ◦ ◦ IC IC 190 190 190 190 190 190 190 190 190 190 190 190 190 190 190 190 190 190 190 190 190 190 190 190 190 190 190 190 190 190 190 190 190 190 190 190 94. . It can be confirmed that the bispyranone compound Α has excellent nitric oxide elimination energy. 0 29 200810751 ^ > It is known that the bis-π-pyramid compound A of the present invention can clearly eliminate - emulsification II, as a vascular system, nerve Systematic, immunological agents are quite useful. The double yarn_compound A has the side that eliminates the excessively normal recovery of the oxygen domain in the living body, and the premature administration of the _-oxygen listener to prevent the production of excess nitrogen oxide in the living body. . That is, in the present specification, the oxygen-aged energy of the compound A in the double (four) side does not mean that all the nitrogen oxides in the body of the sister are completely eliminated, but that the excess nitrogen oxide in the living body is eliminated, and the scale is shouted. Maintain proper weight for the body. [Persistence of peroxynitrite elimination by colorimetry] The peroxinic nitrite elimination ability of the dipyridyl-ruthenium complex A is based on the Griess method's use of N〇2/N〇3 reagent Group (AssayKit) (Colorimetric) (manufactured by Tongren Chemical Co., Ltd.). The known antioxidant substances (_) catechin, maltol, p-coumaric acid were also evaluated, and compared with the dipyridone compound A. The test substance solvent was added to a commercially available flat-bottom 96-well culture dish: a buffer containing 丨% acetonitrile (ρΗ=7.6) 40//L to change the concentration of the test substance. Thereafter, a reductase 10//L and a coenzyme 10//L in the reagent group were added to the respective wells. Add 40//L of SIN-1 (3-(4-Merminyl Morpholinyl) Sydney imine sydnonimine hydrochloride) 50//M as peroxynitrite to produce 30 200810751 9 agent' to make it react at 37 C 2 hours. After completion of the reaction, Griess reagent A in the 50//L reagent group was added, and the mixture was allowed to stand for 5 minutes. Then, 50/L of Griess reagent B was added and left for 1 minute to carry out a color reaction. The versatility of the 54 〇 ship was measured on a multi-function microdisk analyzer. The absorbance of the X test substance is defined as 4. The absorbance of the control group containing no test substance was C540, and the absorbance of the blank group containing no test substance and SIN-1 was b540, and the peroxynitrite elimination rate (%) was obtained by the following formula, as shown in Table 3. Figure 9 shows. Peroxynitrite elimination rate (%) = 100x (1—(S540 — B540) / (C540 — B540)) The calibration curve is a concentration range of 0 to 100//M in the sodium nitrate solution instead of the SIN-1 solution. The absorbance of the set sample is determined to determine the concentration of nitrate ions in the solution. The concentration of peroxynitrite produced by the SIN-i solution can be determined from the nitrate ion concentration. The intensity of the peroxynitrite elimination energy was compared by eliminating the concentration of 5〇% (IC50, //M) in the experimental system. As a result, in the control group, peroxynitrite 8.18 //M ' from 50#M of SIN-1 was produced, and the coffee concentration of 5 〇% of its peroxynitrite was eliminated, which was 24 with respect to the dioxanone compound A. 04/zM, maltitol is 31.84 mM, p-coumaric acid is 31 sen #M, () 儿余素 is 705. 6yM' shows that the bispyranone compound a has excellent peroxynitrite Eliminate energy. 31 200810751 t Table 3
〔路胺酸酶活性阻礙作用的測量〕 ;平底96孔培養胍添加受驗物質溶液i〇〇“L,加入6⑼單位 32 200810751 /ml 末自洋4 (Agaricus bisporus)的酿胺酸酶(tyrosinase) 溶液10//L,30°C下培養i〇分鐘。之後,添加預先於3(Γ(^溫過 的 6mM 的 L-DOPA (L-K3, 4-二經苯基(dihydr0Xyphenyl))丙 氨酸(alanine))溶液100//L,在3(rc下一邊間隔振動4〇分、 -邊培養。受驗物質的溶媒使用含有! %乙腈i _M的琥站酸緩衝 液(ρΗ5· 5) ’酪胺酸酶、L—D〇pA的溶媒使用1〇〇禮的琥珀酸缓衝 液(pH 5· 5)。振動後,以黑色素量指標的475 nm的波長測量吸 光度,將此數值以S475代表。無添加受驗物質的情況為控制組⑹, 其吸光度以a?5,無添加L-D0PA的情況為樣本空白組(SB),其吸 光度以SB”5,無添加樣本與L—D〇pA的情況為控制空白組(cb), 其吸光度以CB475 ,由公式2算出路胺酸酶阻礙率(%)。使用熊果 素(arbutm)(東京化成工業(股)製)作為陽性控制組。 酿胺酸酶活性阻礙率(%) U-…-SBW /⑹ 一 CB475) } } 、、口果"】、、加/辰度lmM的雙併口比喃酮化合物A與熊果素的路胺 酸酶酿率,相對於在雙併_酮化合物A為36· 34%,熊果素為 25· 77/所以可知道雙併吼喃酮化合物a比熊果素更具有優異的 赂胺瞒阻礙雜,顯示出雙併邮謝b合物A的美白作用。 〔於老鼠皮膚触胺酸酶基因表現解析〕 讓老鼠攝食雙併吼喃酮化合物A時,在老鼠皮膚測量將赂胺 33 200810751 « * 酸酶編碼的基因的表現(geneexpressi〇n)。 I ·貫驗動物 系、、先、性別:物種··老鼠、系統:Hos ·· HR1 (無毛η 鼠)、性別:雌性 “、、小 =驗_始週齡:5週齡(飼育丨週後從__外線照 1-3·微生物等級:sPF 1 4·飼者·清水實驗材料股份有限公司 Π·飼育環境 汉疋溫濕度:24±l°c、相對濕度55±5% 空調設備:全新風方式 ^明時間:12小時自動點燈、媳燈方式 飼育設備:塑膠製籠子5隻/1籠 飼料·自由攝取粉末滅菌飼料MF-1 (ORIENTAL酵母工業(股)), 也另外调製混合〇· 1重量%雙併吼細化合物八於心1的飼料。 η驗對象物的投予:使其自由攝取粉末混合飼料。從解剖π小時 前開始斷食。 給水:自由攝取殺菌過的自來水 34 200810751[Measurement of obstruction of guanaminease activity]; Flat-bottom 96-well culture 胍 Add test substance solution i 〇〇 "L, add 6 (9) units 32 200810751 /ml End from the 4 (Agaricus bisporus) of the tyrosinase (tyrosinase ) 10 / / L, cultured at 30 ° C for 1 minute. After that, add 6 mM (L-DO3 (L-K3, 4-diphenyl) Alanine solution 100//L, incubated at 3 (rc) at intervals of 4 、, - cultivating. The vehicle used for the test substance contains: % acetonitrile i _M sulphate acid buffer (ρΗ5· 5 The reagent for 'tyrase and L-D〇pA is succinic acid buffer (pH 5·5). After shaking, the absorbance is measured at a wavelength of 475 nm of the melanin amount. S475 stands for: No control substance added is the control group (6), its absorbance is a?5, no L-D0PA is added as the sample blank group (SB), its absorbance is SB"5, no added sample and L- The case of D〇pA is the control blank group (cb), and its absorbance is CB475, and the guanaminease inhibition rate (%) is calculated by the formula 2. Using arbutin (a) Rbutm) (Tokyo Chemical Industry Co., Ltd.) as a positive control group. Blocking rate of tyrosinase activity (%) U-...-SBW /(6) -CB475) } },,,,,,,,,,,,, The lutein of the lmM is higher than that of the ketone compound A and arbutin, and is 36.34% in the di-ketone compound A, and the arbutin is 25.77. Compound a is superior to arbutin in that it has an excellent hindrance and hindrance, and shows a whitening effect of double-labeled b. A. [Analysis of the expression of the catalinase gene in mice] Let the mice ingest the bis-indolone compound A When measured in mouse skin will be amineamine 33 200810751 « * Acidase-encoded gene expression (geneexpressi〇n). I · Laboratory animal system, first, sex: species · mouse, system: Hos · HR1 ( Hairless η mouse), gender: female ",, small = test _ starting week age: 5 weeks old (after cultivating 丨 丨 from __ outside line 1-3) Microbial level: sPF 1 4 · Feeder · Qingshui experimental materials Co., Ltd. 饲·feeding environment Hanjing temperature and humidity: 24±l°c, relative humidity 55±5% Air conditioning equipment: new wind Type of time: 12 hours of automatic lighting, xenon lamp breeding equipment: 5 plastic cages / 1 cage feed · Free intake of powdered sterilized feed MF-1 (ORIENTAL Yeast Industry Co., Ltd.), also prepared mixed 〇 · 1% by weight of the compound of the bismuth and bismuth compound. η Subject matter administration: It is allowed to freely ingest the powder mixed feed. The fasting begins from the anatomy π hours ago. Water supply: free intake of sterilized tap water 34 200810751
I IV-3.解剖 測里攸解剖18小時前開始斷食的個體的體重測量户水 里測里後错由戊巴比妥麻醉(40mg/kg)的腹腔内投予以:入麻 醉。 切開版部’自心臟進行肝素化(heparinize)採血。接著, 對内臟器官進行肉眼的觀察後,從肝臟、後頭部摘出在臀部的背 部全體的皮膚。關於背部皮膚,將由皮膚組織背側的尾巴根部朝 頭2cm、從腰椎往右側〇. 5cm部位的皮膚切下lcm2 , 經鮑音固定,及石軌埋後保存皮膚組織。其他的背部皮膚則迅 速放入ISf|紙,職減急速冷絲於—8()<t長期保存。 〔關於基因表現解析之實驗〕 從每組選擇其巾兩隻的背部皮膚,抽出用於基因表現解析的 Total RNA樣本。在液態氮存在下將其細細切碎,以溼重量數十 mg分別注入1· 5ml容量之微量離心管(eppend〇rf加⑹。使用 RNase easy mini kit (QIAGEN製)遵從一般的程序來抽出Total 歷。 將抽出的Total RNA照Affymetrix公司建議的順序處理後, 以DNA微陣列(microarray)法來調查皮膚組織的表現樣式 (expression pattern)。具體來說,從抽出的Total RNA使用 「SUPERSCRIPT choice system for cDNA synthesis」(商品名, 35 200810751 tI IV-3. Anatomy The weight of the individual who started the fasting 18 hours before the anatomy was measured by the intraperitoneal injection of pentobarbital anesthesia (40 mg/kg): into the drunk. The cut section was heparinized from the heart for blood collection. Next, the internal organs were visually observed, and the entire back of the buttocks was taken out from the liver and the back of the head. Regarding the back skin, the root of the tail on the back side of the skin tissue is 2 cm toward the head, and the skin from the lumbar vertebrae is cut from the lumbar vertebrae to the right side. The skin of the 5 cm portion is cut into 1 cm 2 , fixed by the bow sound, and the skin tissue is preserved after the stone rail is buried. Other back skins are quickly placed in ISf|paper, and the job-reduction chills are stored in -8()<t for a long time. [Experiment on Analysis of Gene Expression] From each group, the back skin of the two tissues was selected, and Total RNA samples for gene expression analysis were extracted. It was finely chopped in the presence of liquid nitrogen, and a microcentrifuge tube (eppend〇rf plus (6) of a volume of 1.25 ml was injected at a wet weight of several tens of mg. The RNase easy mini kit (manufactured by QIAGEN) was used to follow the general procedure. Total calendar. The total RNA extracted was processed in the order suggested by Affymetrix, and the expression pattern of the skin tissue was investigated by the microarray method. Specifically, the SUPER RNARI selection was used from the extracted Total RNA. System for cDNA synthesis" (trade name, 35 200810751 t
II
Invitrogen公司製)來合成cDNA,將這cDNA作為模板,使用「BioInvitrogen company to synthesize cDNA, use this cDNA as a template, use "Bio
Array High Yield RNA Transcript Labeling Kit」(商品名,EnzoArray High Yield RNA Transcript Labeling Kit" (trade name, Enzo
Diagnostics公司製),將標識維生素H的cRNA在試管内合成。如 此一來,將這cRNA碎片化後,在DNA微陣列(商品名rGeneChipDiagnostics, Inc., synthesizes cRNAs that recognize vitamin H in vitro. As a result, after fragmenting this cRNA, the DNA microarray (trade name rGeneChip)
Mouse Expression Array 430A」(Affymetrix 公司製)和雜交反 應烘箱(hybridization oven)(商品名,Affymetrix 公司製)中 進行雜交培殖,以「Fluidics station」(商品名,Affymetrix 公司製)進行與R-藻紅蛋白鏈親合素(R-phyC〇ery^rin Streptavidin)的反應及洗淨操作之後,以rGene Array Scanner」 (商品名,Affymetrix公司製)測量其螢光強度,進行關連基因 的表現量之解析。此外,上述的DNA微陣列的檢測感度是工: 100, 000,這是在老鼠的total RNA樣本中,添加來自老鼠⑼似 的複製品、已標識完成的複寫產物,檢測出而測定的。關於本實 驗所使用的來自老鼠皮膚的total RNA,檢測出22,69〇個基因, 用於基因表現的增減的解析。其中酪胺酸酶被編碼為pr〇beID : 144882一at ’從其螢光強度求出基因表現強度。 實驗組與對照組的組合如下: 貫驗組:餵食含有0· 1%雙併吡喃酮化合物A的MF—丨食物1〇 週(16週大) 對照組:餵食MF-1食物1〇週(16週大) 36 200810751 > * 表4 探針Probe 登錄編號 Accession No·(人類 human) 登錄編號 Accession No·(小鼠 mouse ) 控制組食物 攝食雙併。比 喃_化合物 A 比例Ratio (攝食雙併 °比喃酮化合 物A/控制 組食物) 1448821_at NM—000372 NM—011661 1276.9 479. 75 0. 37575Mouse Expression Array 430A" (manufactured by Affymetrix Co., Ltd.) and Hybridization Oven (trade name, manufactured by Affymetrix Co., Ltd.) were hybridized and cultured, and "Fluidics station" (trade name, manufactured by Affymetrix Co., Ltd.) and R-algae After the reaction and washing operation of R-phyC〇ery^rin Streptavidin, the fluorescence intensity was measured by rGene Array Scanner (trade name, manufactured by Affymetrix Co., Ltd.), and the amount of related genes was measured. Analysis. Further, the detection sensitivity of the above DNA microarray was: 100,000, which was determined by adding a copy of the mouse (9)-like replica and the identified completed copy product in the total RNA sample of the mouse. About the total RNA from mouse skin used in this experiment, 22,69 genes were detected for analysis of the increase or decrease of gene expression. The tyrosinase was encoded as pr〇beID: 144882-at' to determine the gene expression intensity from its fluorescence intensity. The combination of the experimental group and the control group was as follows: The test group: MF-丨 food containing 0·1% bispyranone compound A was fed for 1 week (16 weeks old) Control group: MF-1 food was fed for 1 week (16 weeks old) 36 200810751 > * Table 4 Probe Probe Login No. Accession No· (Human human) Login No. Accession No· (mouse mouse) Control group food intake double. Ratio 喃 _ compound A ratio Ratio (ingestion double ° 比 ketone compound A / control group food) 1448821_at NM—000372 NM—011661 1276.9 479. 75 0. 37575
此外,表4中的「Accession No·」是各基因在GenBank (NCBI 的核酸排列資料庫)的識別號碼,Probe Set ID是Affymetrix 公司製造的GeneChip Expression Array的固有識別號碼。 從表4可以了解,老鼠皮膚組織上的酪胺酸酶的基因表現因 雙併吼喃酮化合物A而受到抑制,出現於皮膚上的酪胺酸酶的過 剩表現被抑制,由於酪胺酸酶所形成的黑色素,因雙併吡喃酮化 合物A而受到抑制。 〔皮膚組織裡增生細胞核抗原(Proliferation CeH Nuciear Antigen)之測定〕 增生細胞核抗原(PCNA)由免疫組織中以化學的方法來測定。 關於已埋妥石蠟包的老鼠皮膚組織,遵照習知既定方法脫石 蠟處理,在0· 01M檸檬酸緩衝液(ρΗ6· 〇)中微波處理五分鐘來進 仃抗原賦活化。冷卻至室溫後,在常溫下以含有〇· 3%過氧化气的 曱醇進行反學化應20分鐘,以阻礙其内因性的的過氧化酶。水洗、 10mM PBS (-)洗淨後,以兔子血清75倍1〇福ρ 37 200810751 釋/谷液貝把5分鐘的微波處理,區隔終了後將兔子 血清去掉,添加稀釋500倍的1次抗體(PC10 ·· DAK0製),以20 分鐘的微波處理使其反應。以1QmMpBS (―)進行兩次洗淨,添加 稀釋3Q(H口、准生素η化的二次抗體(維生素η化兔子免疫球蛋白 M,DAK〇製),進行5分鐘的微波處理使其反應。以lOmMPBS (sj 進行兩次洗淨,添加胤試薬(ABC-HRP ; VeCtastain製)進行5 分鐘的微波處理使其反應。使㈣AB (3, 3_二氨基聯苯胺鹽酸鹽 (Diamnobenzidine tetrahydrochloride) : DAK0 製)為成色試 劑,在常溫下放置3分30秒使其反應。水洗後,基於習知方法來 脫水,進行封入處理。在顯微鏡下觀察皮膚組織的染色狀況。經 過紫外_射10週10週的檢體,由於PCNA的增加,表皮細胞的 要的、、、田I核上色,使用Adobe Photoshop取得圖像,將圖像中 疋面和裡的染色處,以NIH Imaging數值化。 將各組的數值求出平均值土S.D·。兩組間的顯著差異檢定以uv (—)組為基準值丨,補正各組的平均值後,實施3加此时,s est (”、、員著水準ρ<〇· 〇5)。測定的樣本如表5,結果如圖所 示。 攝取雙併吡喃酮化合物Α的老鼠其皮膚組織中pCNA並未增 加。PCNA可用來氧化或切斷麵,以及當作增_皮膚疾病患者 所熟知、乾癬的生物標誌(biomarker)時的表現上升,本實驗中 對老鼠的皮膚進行紫外線照射而表現上升的PCNA,因食用雙併吼 38 200810751 紫外線輻射的緩和作 喃酮化合物A所產生的DNA氧化防止作用 用,而回到正常水平。 表5 1 —— 未照射紫外線 控制組食物 2 紫外線照射 -—— 控制組食物 ^〜〜 3 紫外線照射 混合0· 1%雙併,_化合物 4 紫外線照射 混合0· 05%雙併吼伽化合物'^ 5 紫外線照射 混合〇.G1%雙併 <轴化 6 紫外線照射 混合〇· 05% /3胡蘿蔔素的飼料一 ^ 7 紫外線照射 混合0.01%/3胡蘿蔔素的飼料一' ' 〔皮膚組織中兜甲蛋白(loricrin)之測定〕 兜曱蛋白由免疫組織以化學方法來測定。 已埋妥石虫鼠包的老鼠皮膚組織,照習知既定方法脫石 理’在0. 01M檸檬酸緩衝液(pH6. 〇)中微波處理5分鐘來進行 原賦活化。冷卻至室溫後,在常溫下以含有G. 3%過氧化氫的甲= 進行反學倾20分鐘,雜礙其_㈣的魏化酶。水洗、_ PBS (-)洗淨後’以山羊血清75倍顧哪㈠的稀釋溶液 實施5分鐘的微波處理使其區隔,區隔終了後將山羊血清去掉, 添加稀釋500倍的1次抗體(Loricrin Polyclonai Ar^body,Purified : Sigma製)’以2〇分鐘的微波處理使抗體反 39 200810751 應。之後以10mM PBS ( —)進行兩次洗淨,添加稀釋3〇〇倍維生 素Η化的二次抗體(維生素Η化山羊免疫球蛋白Μ ; DAK0製),進 行5分鐘的微波處理使抗體反應。以l〇mM PBS (〜)進行兩次洗 淨,添加ABC試薬(ABC-HRP ; Vectastain製)進行5分鐘的微波 處理使其反應。使用DAB (3, 3-二氨基聯苯胺鹽酸鹽:DAK〇製) 為成色试劑’在常溫下放置四分三十秒使其反應。之後以蘇木素 (Hematoxylin)對細胞核或組織全體作染色處理。水洗後,基於 習知方法來脫水,進行封入處理。在顯微鏡下觀察皮膚組織的染 色狀況。經過紫外線照射10週的檢體,由於兜甲蛋白的增加,表 皮細胞的主要的細胞核上色,使用Ad〇be ph〇t〇sh〇p取得圖像, 將圖像中一定面積裡的染色處,以NIH Imaging數值化。測定的 樣本如表6,結果如圖π所示。 將各組的數值求出平均值±S.D.。兩組_顯著差異檢定以爪 (―)組為基準值1,補正各組的平均值後,實施student,s t-test (顯著水準 p<〇. 〇5)。 攝取又併吡喃酮化合物A的老鼠其皮膚組織中兜甲蛋白並未 曰力a甲蛋自已知可作為皮膚終末分化的生物標誌、,可抑制因 攝取雙併料_化合物A雌生的減老化現象,並保持正常皮 200810751 表6 1 未照射紫外線 —-—— 控制組食物 ~ 2 紫外線照射 控制組食物 c\ —~~-~~_ 紫外線照射 ^-------- 3 混合0· 1%雙併吼喃嗣化合物Α的飼料 4 紫外線照射 —--- —----- 混合0· 05%雙併吼喃酮化合物a的飼料 5 紫外線照射 -~~~—__ --—— 混合0· 01%雙併呢喃酮化合物A的飼料 6 紫外線照射 ------- 混合0.05% yS胡蘿蔔素的飼料 7 备、外線照射 混合0.01%/5胡蘿蔔素的飼料 〔皮膚組織中角蛋白1型(keratin 1)之測定〕 角蛋白1型由免疫組織化學方法來測定。 已埋妥石包的老鼠皮膚組織,遵照習知既定方法脫石堪處 理,在〇· 01M擰檬酸緩幾液(ρΗ 6· 〇)中微波處理5分鐘來進行 抗原賦活化。冷卻至室溫後,在常溫下以含有〇· 3%過氧化氫的甲 醇進行反學化應2G分鐘,雜礙其關性的的過氧化酶。水洗、 lOmM PBS (-)洗淨後,以山羊血清75倍麵pBS )的稀 釋溶液實施5分鐘的微波處理使其區隔,區隔終了後將山羊血清 去掉,添加稀釋500倍的1次抗體(Mouse Keratinl (AF109) Polyclonal Antibody,Purified ·· C0VANCE 製),以 20 分鐘的微 波處理使抗體反應。以(—)進行兩次洗淨,添加稀釋 300倍維生素η化的二次抗體(維生素η化山羊免疫球蛋白m;dak〇 41 200810751 製)’進行5分鐘的微波處理使抗體反應。以1〇mMPBS )進行 兩人洗/爭’添加Age試薬(ABC-HRP ; Vect as tain製)進行5分鐘 的微波處理使其反應。使用DAB (3, 3-二氨基聯苯胺鹽酸鹽:DAK0 為成色式劑,在常溫下放置3分30秒使其反應。之後以蘇木 素對細胞核或組織全體作染色處理。水洗後,基於習知方法來脫 水,進行封入處理。在顯微鏡下觀察皮膚組織的染色狀況。經過 I外線知射1〇週的檢體,由於角蛋白1型的增加,表皮細胞的主 要的、、、田胞核上色,使用Ad〇be Photoshop取得圖像,將圖像中一 定面積裡的染色處,以NIH Imaging數值化。測定的樣本如表7, 結果如圖12所示。 將各組的數值求出平均值±SD.。兩組間的顯著差異檢定以uv (―)組為基準值1,補正各組的平均值後,實施student,s t—test (顯著水準 p<〇〇5)。 攝取雙併吡喃鲷化合物A的老鼠其皮膚組織中角蛋白丨型並 未增加。肖蛋自1型已知可作為皮膚終末分化·物標誌、,可抑 制因攝取雙併π比_化合似職生的皮膚老化現象,並保持正 常皮膚的分化狀態。 42 200810751 表7 1 未照射紫外線 — _ ' -—~~~~~— 控制組食物 2 紫外線照射 ~~~______ 控制組食物 3 紫外線照射 —— 混合0· 1%雙併吧喃_化合物Α的飼料 4 紫外線照射 -^ 混合0· 05%雙併呢喃_化合物A的飼料 5 紫外線照射 ----_ 混合0· 01%雙併呢喃_化合物A的飼料 6 ---- 紫外線照射 --S_______ 混合0.05%万胡蘿萄素的飼料 7 ~-----— 紫外線照射 ——^___ 心合〇· 01%/5胡蘿勤素的飼料 --·—---- 處方例如下: 〔處方例1:膠囊〕 將下列成分混合’充填至混合了霄(gelatin)及甘油的膠 囊基劑中,得到軟膠嚢 (配合量;mg) 70 30 10 110 (組成) 雙併"比喃_化合物A 三烯生育醇 蜜蠟 葡萄籽油 〔處方例2 ··錠劑〕 將下列成分混合、打錠而成錠劑。 43 200810751 (組成) 雙併吼喃酮化合物A 纖維素 殿粉 (配合量;mg) 75 40 20 蔗糖脂肪酸酯 2 〔處方例3 :錠劑〕 將下列成分混合、打錠而成錠劑。 (組成) 雙併°比喃酮化合物A 纖維素 (配合量;mg) 75 40 澱粉 20 庶糖脂肪酸S旨 2 〔處方例4:果汁〕 (組成) 果糖葡萄糖液糖 檸檬酸 抗壞血酸(L-Ascorbic acid) 香料 (配合;質量%) 5.00 10.40 0.20 0.02 色素 0.10 44 200810751 雙併吼喃_化合物A 水 0.05 84.33 〔處方例5:乳霜〕 成八成分⑴〜(1°)溶解,力伽。C使其呈油相。將 刀 〜(13)溶解,加熱至啊使其呈水相。慢 加入油相中使其乳化,-邊祕冷卻至靴,更進—蝴=相 至30 C就得到乳霜。 半令部 (1) 十八垸醇(stearyl alcohol) (2) 硬脂酸 (3) 氫化羊毛脂(hydrogenated lanolin) (4) 絞鯊烯(squalan) (5) 二辛基十二烧醇(〇ctyi d〇decan〇1) (6) POE (25)錄犧醇_ (cetyl alcohol ether) (7) 單硬酯酸甘油酯(glyceryl monostearate) (8) 雙併吡喃酮化合物a (9) 防腐劑 (10) 香料 (11) 1,3 丁二醇(butylene glycol) (12) PEG 1500 (13) 精製水 6. 2· 10 0· 適量 適量 6.0 殘餘 45 200810751 【圖式簡單說明】 圖1為表示敏紋分數的圖表。 圖2為表示皮膚水分量的圖表。 圖3為表示皮膚硬度的圖表。 圖4為表示默化蛋白質量(相對値)的圖表。 圖5為表示皮膚組織中的8_經基2, _脫氧鳥嗓呤核的量(相對値) 的圖表。 圖6為表示皮膚組織中的過氧化脂質量的圖表。 由卿法產生的一氧化氮消除能的圖表。 圖8為表示比色法(Griess法)一氧化氮消除能的圖表。 圖9為表示比色法過氧亞硝基漏除能的圖表。 圖10為表示PCNA增加抑制能力的圖表。 圖11為表7F兜甲蛋白抑制能力的圖表。 圖12為表示角蛋白1型抑雛力的圖表。 【主要元件符號說明】 46In addition, "Accession No." in Table 4 is the identification number of each gene in GenBank (NCBI's Nucleic Acid Arrangement Database), and Probe Set ID is the unique identification number of the GeneChip Expression Array manufactured by Affymetrix. As can be seen from Table 4, the gene expression of tyrosinase on mouse skin tissue was inhibited by the dipyrone ketone compound A, and the excess performance of tyrosinase present on the skin was inhibited due to tyrosinase The melanin formed is inhibited by the dipyridone compound A. [Measurement of Proliferation CeH Nuciear Antigen in Skin Tissue] Proliferating cell nuclear antigen (PCNA) is chemically determined from immune tissues. Regarding the skin tissue of the mouse which had been embedded in the paraffin pack, it was subjected to dewaxing treatment according to a conventional method, and microwave activation was carried out in a 1.0 M citrate buffer (ρΗ6·〇) for five minutes to effect antigen activation. After cooling to room temperature, it was neutralized at room temperature for 20 minutes with decyl alcohol containing 〇·3% peroxygen gas to hinder its endogenous peroxidase. After washing with water and 10 mM PBS (-), the rabbit serum was 75 times 1 〇 ρ ρ 37 200810751 release / 谷液贝 for 5 minutes of microwave treatment, after the interval was separated, the rabbit serum was removed, and the dilution was added 500 times once. The antibody (manufactured by PC10··DAK0) was reacted by microwave treatment for 20 minutes. The cells were washed twice with 1Q mM pBS (-), and diluted with 3Q (H-port, ginseng-nized secondary antibody (vitamin η-treated rabbit immunoglobulin M, manufactured by DAK)), and subjected to microwave treatment for 5 minutes. The reaction was carried out by washing twice with 10 mM PBS (sj, adding hydrazine test (ABC-HRP; manufactured by VeCtastain) for 5 minutes by microwave treatment. (4) AB (3, 3-diaminobenzidine tetrahydrochloride) : DAK0) is a color forming reagent, which is allowed to stand at room temperature for 3 minutes and 30 seconds to react. After washing with water, it is dehydrated according to a conventional method, and is sealed. The staining state of the skin tissue is observed under a microscope. In the sample of 10 weeks of the week, due to the increase of PCNA, the epidermis cells were colored, and the field I was colored. The image was taken using Adobe Photoshop, and the stained area in the image and the inside of the image was quantified by NIH Imaging. The average value of each group is determined as SD. The significant difference between the two groups is determined by the uv (-) group as the reference value. After correcting the average value of each group, 3 plus is performed, s est (" , and the level of the staff ρ < 〇 · 〇 5). The sample is shown in Table 5. The results are shown in the figure. The mice ingested with the bispyranone compound 并未 did not increase the pCNA in the skin tissue. PCNA can be used to oxidize or cut the surface, and as a patient with skin disease The performance of the well-known, cognac biomarker increased. In this experiment, the PCNA of the mouse's skin was irradiated with ultraviolet rays, and the PCNA was increased due to the consumption of the dipyridamole 38 200810751. The ultraviolet radiation was alleviated as the DNA produced by the ketone compound A. Oxidation prevention function, and return to normal level. Table 5 1 - Unirradiated UV control group food 2 UV irradiation - - Control group food ^~~ 3 UV irradiation mixing 0·1% double, _ compound 4 UV irradiation Mix 0. 05% double samarium compound '^ 5 UV irradiation mixed 〇.G1% doubling <axisization 6 UV irradiation mixed 〇· 05% /3 carotene feed one ^ 7 UV irradiation mixing 0.01%/3 Feed of carotene - 'Determination of loricin in skin tissue】 The protein of the scorpion protein is chemically determined from the immune tissue. The mouse has been buried in the stone worm. The skin tissue was subjected to microwave treatment in a 0.01 M citrate buffer (pH 6. 〇) for 5 minutes to carry out the original activation. After cooling to room temperature, it was contained at room temperature to contain G. 3 . % of hydrogen peroxide is reversed for 20 minutes, which interferes with its _ (four) Weiwei enzyme. After washing, _ PBS (-) after washing, it is carried out for 5 minutes with a diluted solution of goat serum 75 times. The cells were isolated by microwave treatment, and the goat serum was removed after the separation. The antibody was diluted 500-fold (Loricrin Polyclonai Ar^body, manufactured by Sigma). The antibody was treated by microwave treatment for 2 minutes. . Thereafter, the cells were washed twice with 10 mM PBS (-), and a secondary antibody (vitaminated goat immunoglobulin oxime; manufactured by DAK0) diluted with 3 valavirin was added thereto, and subjected to microwave treatment for 5 minutes to react the antibody. The cells were washed twice with 1 mM PBS (~), and ABC test (ABC-HRP; manufactured by Vectastain) was added for microwave treatment for 5 minutes to cause a reaction. DAB (3,3-diaminobenzidine hydrochloride: manufactured by DAK) was used as a color forming reagent to allow the reaction to stand at room temperature for four minutes and thirty seconds. The nucleus or tissue is then stained with Hematoxylin. After washing with water, it is dehydrated based on a conventional method and subjected to encapsulation treatment. The staining of the skin tissue was observed under a microscope. After 10 weeks of exposure to ultraviolet light, the main nucleus of the epidermal cells is colored due to the increase of the armor protein, and the image is obtained using Ad〇be ph〇t〇sh〇p, and the staining area in a certain area of the image is obtained. , digitized by NIH Imaging. The measured samples are shown in Table 6, and the results are shown in Figure π. The values of the respective groups were averaged ± S.D. The two groups _ significant difference test was based on the claw (-) group as the reference value 1. After correcting the average value of each group, implement student, s t-test (significant level p < 〇. 〇 5). The mice ingested with pyrone compound A have no thyroin in their skin tissue. They are known as biomarkers for terminal differentiation of skin, and can inhibit the reduction of females due to ingestion of double-blends. Aging phenomenon, and maintain normal skin 200810751 Table 6 1 Unirradiated UV--- Control group food ~ 2 UV irradiation control group food c\ —~~-~~_ UV irradiation ^-------- 3 Mix 0·1% bismuth oxime compound Α feed 4 UV irradiation ----------- Mix 0· 05% bis-indolone compound a feed 5 UV irradiation-~~~-__ - - Mix 0. 01% dipyridone compound A. 6 UV irradiation ------- Mix 0.05% yS carotene feed 7 Prepare, mix externally with 0.01%/5 carotene feed [skin Determination of keratin 1 in tissues] Keratin type 1 was determined by immunohistochemistry. The skin tissue of the rats that have been buried in the stone bag is treated according to the conventional method, and the antigen is activated by microwave treatment for 5 minutes in a 〇· 01M citric acid solution (ρΗ 6· 〇). After cooling to room temperature, the decontamination at room temperature with methanol containing 3% 3% hydrogen peroxide should be 2 G minutes, and the peroxidase which is obstructive to it. After washing with water and lOmM PBS (-), the diluted solution of goat serum 75 times pBS) was subjected to microwave treatment for 5 minutes to separate it. After the separation, the goat serum was removed, and the antibody diluted 500 times was added. (Mouse Keratinl (AF109) Polyclonal Antibody, Purified · C0VANCE), reacted with antibodies for 20 minutes of microwave treatment. The cells were washed twice (-), and a secondary antibody diluted with 300 times of vitamin η (vitamin η goat immunoglobulin m; dak〇 41 manufactured by 200810751) was added to carry out microwave treatment for 5 minutes to react the antibody. Two people were washed and challenged with 1 mM PBS. The Age test (ABC-HRP; manufactured by Vect as tain) was subjected to microwave treatment for 5 minutes to cause a reaction. DAB (3,3-diaminobenzidine hydrochloride: DAK0 is used as a color forming agent, and allowed to stand at room temperature for 3 minutes and 30 seconds for reaction. After that, the nucleus or tissue is stained with hematoxylin. After washing, based on the habit The method of dehydration is carried out, and the encapsulation treatment is carried out. The staining state of the skin tissue is observed under a microscope. The sample which is detected by the I line for 1 week, the main, and the nucleus of the epidermal cell due to the increase of the keratin type 1 Coloring, using Ad〇be Photoshop to obtain images, the staining area in a certain area of the image is quantified by NIH Imaging. The measured samples are shown in Table 7, and the results are shown in Fig. 12. The numerical values of each group are obtained. Mean ± SD. The significant difference between the two groups was determined by using the uv (-) group as the reference value 1. After correcting the average of each group, implement student, st-test (significant level p < 〇〇 5). The keratin 丨 type in the skin tissue of the mice with pyryl ruthenium compound A was not increased. Xiao egg from the type 1 is known to be a marker of skin terminal differentiation and differentiation, and can inhibit the incorporation of bis and π ratios. Skin aging and keep normal skin 42 200810751 Table 7 1 Unirradiated UV - _ ' - -~~~~~ - Control group food 2 UV irradiation ~~~______ Control group food 3 UV irradiation - Mix 0·1% double and mutter _ compound Α feed 4 UV irradiation - ^ Mix 0 · 05% double whisper _ compound A feed 5 UV irradiation --- _ mixed 0 · 01% double whisper _ compound A feed 6 ---- UV Irradiation--S_______ Mixing 0.05% yoghurt feed 7 ~------UV irradiation——^___ 心合〇· 01%/5Carotene feed------- The prescription is as follows: [Prescription Example 1: Capsule] The following ingredients are mixed and filled into a capsule base in which gelatin and glycerin are mixed to obtain a soft capsule (combination amount; mg) 70 30 10 110 (composition) And "Biam_Compound A Triene tocopherol wax seed oil [Prescription Example 2 ··Latch] The following ingredients are mixed and tableted into a tablet. 43 200810751 (Composition) Bis(A) ketone compound A Cellulose powder (combination amount; mg) 75 40 20 sucrose fatty acid ester 2 [Prescription Example 3: Lozenge] Mix the following ingredients Ingots, tablets, tablets, tablets, tablets, tablets, ketones, sucrose, sucrose, sucrose, sucrose, sucrose, sucrose, sucrose Ascorbic acid citrate (L-Ascorbic acid) Perfume (combination; mass%) 5.00 10.40 0.20 0.02 Pigment 0.10 44 200810751 Double 吼 _ _ Compound A Water 0.05 84.33 [Prescription Example 5: Cream] into eight ingredients (1) ~ (1 ° ) dissolve, force gamma. C makes it an oil phase. Dissolve the knife ~ (13) and heat it to make it an aqueous phase. Slowly add to the oil phase to emulsify, - secretly cool to the boot, more into the butterfly - phase to 30 C to get the cream. Semi-order (1) stearyl alcohol (2) stearic acid (3) hydrogenated lanolin (4) squalan (5) dioctyldodecanol ( 〇ctyi d〇decan〇1) (6) POE (25) cetyl alcohol ether (7) glyceryl monostearate (8) bispyranone compound a (9) Preservatives (10) Perfume (11) 1,3 Butanediol (12) PEG 1500 (13) Refined water 6. 2· 10 0· Appropriate amount 6.0 Residue 45 200810751 [Simple diagram] Figure 1 A chart showing the sensitivity score. Fig. 2 is a graph showing the amount of skin moisture. Fig. 3 is a graph showing skin hardness. Figure 4 is a graph showing the amount of protein (relative to enthalpy). Fig. 5 is a graph showing the amount (relatively enthalpy) of the 8-trans-base 2,-deoxyguanine nucleus in the skin tissue. Figure 6 is a graph showing the quality of peroxidized lipids in skin tissue. A graph of the elimination of nitric oxide produced by the Qing method. Fig. 8 is a graph showing the nitric oxide elimination energy by the colorimetric method (Griess method). Figure 9 is a graph showing the colorimetric peroxynitrite leakage energy. Fig. 10 is a graph showing the increase in inhibition ability of PCNA. Figure 11 is a graph showing the inhibition ability of Table 7F. Fig. 12 is a graph showing the stimulating power of keratin type 1. [Main component symbol description] 46
Claims (1)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006120076 | 2006-04-25 |
Publications (2)
Publication Number | Publication Date |
---|---|
TW200810751A true TW200810751A (en) | 2008-03-01 |
TWI383793B TWI383793B (en) | 2013-02-01 |
Family
ID=38655358
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW096113903A TWI383793B (en) | 2006-04-25 | 2007-04-20 | A skin oxidative agent, a skin whitening improving agent, a wrinkle improving agent, a skin relaxation improving agent, a skin water content improving agent, a whitening agent, a melanin inhibitor, a nitric oxide eliminating agent, and an oxidative prevention agent agent |
Country Status (6)
Country | Link |
---|---|
JP (1) | JP5266046B2 (en) |
KR (1) | KR101347442B1 (en) |
CN (2) | CN102626373B (en) |
HK (1) | HK1171661A1 (en) |
TW (1) | TWI383793B (en) |
WO (1) | WO2007125832A1 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102010054149A1 (en) * | 2010-12-10 | 2012-06-14 | Merck Patent Gmbh | 2-pyrones |
JP5770576B2 (en) * | 2011-09-13 | 2015-08-26 | 株式会社ファンケル | Adiponectin production promoter containing helipyrone A as an active ingredient |
JP6054102B2 (en) * | 2012-08-31 | 2016-12-27 | 株式会社ファンケル | Nitric oxide production promoter or inducer |
JPWO2015012194A1 (en) * | 2013-07-22 | 2017-03-02 | 学校法人麻布獣医学園 | Hepirone A improves male sexual function |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001322932A (en) * | 2000-05-16 | 2001-11-20 | Pola Chem Ind Inc | Active oxygen scavenger and active oxygen scavenging composition containing the same |
FR2819718B1 (en) * | 2001-01-22 | 2005-02-25 | Codif Internat Sa | COSMETIC PRODUCT |
JP4373634B2 (en) * | 2001-11-02 | 2009-11-25 | 焼津水産化学工業株式会社 | Nitric oxide scavenger |
JP4285939B2 (en) * | 2002-04-25 | 2009-06-24 | 株式会社ノエビア | Topical skin preparation |
JP2005068103A (en) * | 2003-08-27 | 2005-03-17 | We'll Corporation:Kk | Cosmetic for skin |
JP4643208B2 (en) * | 2003-09-10 | 2011-03-02 | 文陽 江口 | Antioxidant, whitening agent, and external preparation for skin containing the same |
JP4669670B2 (en) * | 2004-06-04 | 2011-04-13 | 株式会社ロッテ | Anti-influenza virus agent and influenza infection suppression product obtained by adsorbing, impregnating and adding the same |
JP2006008566A (en) * | 2004-06-24 | 2006-01-12 | Ichimaru Pharcos Co Ltd | Cosmetic agent containing lactic acid bacteria fermentation product of fruit juice as active ingredient and its application |
JP4438706B2 (en) * | 2005-07-05 | 2010-03-24 | 花王株式会社 | Antioxidant, perfume composition and cosmetic composition |
-
2007
- 2007-04-20 WO PCT/JP2007/058643 patent/WO2007125832A1/en active Application Filing
- 2007-04-20 KR KR1020087021465A patent/KR101347442B1/en active IP Right Grant
- 2007-04-20 JP JP2008513175A patent/JP5266046B2/en active Active
- 2007-04-20 CN CN201210080551.4A patent/CN102626373B/en not_active Expired - Fee Related
- 2007-04-20 TW TW096113903A patent/TWI383793B/en not_active IP Right Cessation
- 2007-04-20 CN CNA2007800065714A patent/CN101389327A/en active Pending
-
2009
- 2009-04-21 HK HK12112433.6A patent/HK1171661A1/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
TWI383793B (en) | 2013-02-01 |
JPWO2007125832A1 (en) | 2009-09-10 |
CN102626373B (en) | 2014-08-06 |
KR20080110742A (en) | 2008-12-19 |
WO2007125832A1 (en) | 2007-11-08 |
CN102626373A (en) | 2012-08-08 |
KR101347442B1 (en) | 2014-01-02 |
HK1171661A1 (en) | 2013-04-05 |
JP5266046B2 (en) | 2013-08-21 |
CN101389327A (en) | 2009-03-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2784895C (en) | Paxillin stimulating compositions and cosmetic uses thereof | |
TW200423961A (en) | Composition for promoting production of type I collagen and/or elastin | |
WO2006025307A1 (en) | Wrinkle reduction agent, lipolysis accelerator, composition for external use on skin, and food or beverage composition | |
KR102186872B1 (en) | Skin whitening composition comprising milk exosomes | |
WO2012099449A2 (en) | Novel use of flavone-based compound | |
CN101495183A (en) | Treating muscular disorders and improving muscular function | |
JP2008291004A (en) | Composition for beautiful skin | |
CN106413678A (en) | Composition containing fucosterol for skin whitening or moisturizing | |
US20120225141A1 (en) | Substance for restoring normal co-expression and interaction between the lox and nrage proteins | |
TW200810751A (en) | Singlet oxygen scavenger, anti-skin-aging agent, anti-wrinkle agent, anti-sagging agent, agent for improving moisture content in the skin, skin-whitening agent, melanin formation inhibitor, nitrogen monooxide scavenger and antioxidant, each utilizing | |
KR101996732B1 (en) | Cosmetic composition comprising concentrate of Omegiju fermented using magma seawater for improving wrinkles, elasticity or moisturizing the skin | |
TW202102250A (en) | Fermentation product of black rice extract and preparation and use of the same | |
JP2023103376A (en) | Composition for inhibiting cortisone reductase | |
KR20200081600A (en) | Cosmetic composition comprising cereal fermented extract | |
KR100701272B1 (en) | Compositions having inhibitory effect on induction of white hair and positive effect on induction of black hair | |
CN106999528A (en) | For preventing hair loss or stimulating the composition for including high mountain radix scutellariae extract of natural on-off cycles of hair growth | |
JP2005104886A (en) | Collagen synthesis promoter, fibroblast proliferation promoter, cyclic amp phosphodiesterase inhibitor, thyrosinase inhibitor, blood platelet coagulation inhibitor, and cosmetic and food/drink | |
KR101989067B1 (en) | Composition Containing Coumestrin | |
JP2019104730A (en) | Composition for raising cognitive function | |
KR102299417B1 (en) | Composition for inducing alteration of surrounding environment of a aged cell | |
KR102200546B1 (en) | Composition for inducing alteration of surrounding environment of a aged cell | |
JP2008308436A (en) | Antioxidant, anti-aging agent, anti-inflammatory agent, skin cosmetic, and food/drink for beauty culture | |
JP2005281174A (en) | Active oxygen eliminating agent | |
JP2009091302A (en) | Anti-inflammatory agent, immunostimulator, skin whitening agent, anti-aging agent, anti-obesity agent, external preparation for skin, and food/drink for cosmetological use | |
JP3747223B2 (en) | Active oxygen scavenger |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Annulment or lapse of patent due to non-payment of fees |